Full title: Individual longitudinal compliance to neglected tropical disease mass drug administration programmes, a systematic review (122 chars)

Short title: Individual longitudinal compliance to NTD MDA: a systematic review (66 chars)

Authors: Rosie Maddren¹ (corresponding author), Santiago Rayment Gomez¹, Kathryn Forbes¹², Ben Collyer¹,

Klodeta Kura¹, Roy Anderson¹

Affiliations:1 – Department of Infectious Disease Epidemiology, Imperial College London, Saint Mary's Campus,

Norfolk Place, London, W2 1PG

2 – London Centre for Neglected Tropical Disease Research (LCNTDR)

Author contributions: RM reviewed all papers. SRG, BC, KK and RA all reviewed a proportion of all included

papers. Formal data analysis was conducted by RM. Manuscript was reviewed by RM, SRG, KF, and RA.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Abstract (299 words)

Repeated rounds of mass drug administration are the mainstay of transmission control for five of the 20 recognised neglected tropical diseases (NTDs); soil-transmitted helminths, schistosomiasis, lymphatic filariasis, onchocerciasis and trachoma. MDA programme efficiency is reliant upon participants swallowing treatment consistently at each treatment round, measured by the parameter compliance; the proportion of eligible participants swallowing treatment. Individually linked longitudinal compliance data is crucial for assessing MDA programmes, as such data will elucidate treatment behaviour patterns. Accurate monitoring of compliance across species will require the unanimous acceptance of epidemiological parameters across the research community. This review aims to update the review previously completed by Shuford et al (2016), which predominantly highlighted the interchange of parameters coverage (receiving treatment) and compliance (swallowing treatment). This review aims to find to collect the latest longitudinal compliance data reported by control programmes globally for the five MDA controllable species, searching PubMed and Web of Science in January 2022 for articles written since 2016 in English and Spanish. The review adhered to PRISMA guidelines and is registered with PROSPERO (registration number: CRD42022301991). Study title screening was aided by Rayyan, a machine learning software. Studies were considered for inclusion if primary compliance data for more than one time point, in a population larger than 100 participants were identified. All data analysis was conducted in R. A total of 89 studies were identified containing compliance data, 57 were longitudinal studies, 25 of which reported individually linked data which were analysed further. The association of increasing age with systematic treatment during was commonly reported. The review is limited by paucity of data. It is recommended for WHO to clearly define coverage, compliance, and longitudinal compliance in their treatment guides. Current definitions for species-specific guides contradict each other which may influence the incongruency seen definitions seen in this review.

Author summary (158 words)

Neglected tropical diseases (NTDs) affect 1.74 billion people globally, often those in low socio-economic communities in tropical and sub-tropical climates. Five NTDs can be effectively treated using repeated administration of drugs across endemic communities, described as mass-drug administration (MDA). Repeated treatment is necessary due to re-infection of treated people by untreated people in these endemic communities. As such, increasing the number of people treated at each round is clearly critical to increase the number of

parasite-free individuals, which will then latterly reduce the amount of re-infection to the community and therefore increase the chance of reaching elimination of transmission. Currently, the measurement of MDA success is focused upon coverage, the *acceptance* of treatment. However, not everyone who accepts treatment *swallows* the treatment, which arguably is more important to measure as it records the reality of the MDA success. This review aims to capture all the papers providing compliance data for soil-transmitted helminths, schistosomiasis, lymphatic filariasis, onchocerciasis and trachoma.

Introduction

There are 1.74 billion people requiring interventions against neglected tropical diseases (NTDs). This has reduced by 600 million since 2010, yet considerable progress is still required to reduce the global burden of disease (1). The recently published WHO 2030 roadmap clearly demonstrates the link between socioeconomic disparity and NTD burden, with maps displaying GDP per capita and global NTD burden presenting two analogous images (1). NTDs are physically and financially devastating, and infection status (often resultant from poor hygiene or living conditions due to poverty) can further reduce an individual's potential to earn, creating a downward spiral of well-being. As NTDs disproportionately affect individuals of low socioeconomic status, self-funded care is unfeasible for most affected, making global control of parasites predominantly reliant upon donations from pharmaceutical companies and operational support from international non-governmental organisations.

There are 20 NTDs recognised by WHO, five of which are responsible for the majority of the global NTD burden, namely lymphatic filariasis, onchocerciasis, schistosomiasis, soil-transmitted helminths (STH), and trachoma. These can by effectively treated with PC, significantly reducing morbidity. Entire endemic communities or at-risk subgroups receive mass drug administration (MDA) to treat the infection and control parasite transmission. Prior infection or treatment does not confer immunity to the parasite, thus repeated treatments are necessary due to re-infection of treated individuals by those who were not. These individuals who are not treated will continue to harbour parasites, and reinfection events will be common as transmission occurs through ingestion or contact with infectious larvae or parasite eggs found in human excreta, a pathway enabled in environments where sanitation is poor. Compliance (receiving and swallowing of drugs) across the targeted eligible population rarely, if ever, reaches 100%. This also results in the need for repeated treatments to lower parasite prevalence (2). The frequency and time interval between these repeated treatments is dependent upon prevalence levels and the life expectancy of the parasites' infectious stage (2,3). Since the increased efforts of NTD control inspired by the


2012 London Declaration (4), parasite prevalence levels have dropped sufficiently in some communities for elimination of transmission to be considered, thus requiring enhanced monitoring of current MDA activities and related parameters.

The success of MDA programmes should focus on the longitudinal patterns of treatment over time, rather than evaluating each MDA treatment round as a unique activity. Individual treatment history can be categorised as either non-treated (never treated), partially treated, or systematically treated. The longitudinal behaviour of these treatment categories can then be described as systematic (behaviour at round x, is dependent upon the behaviour at round x-1) or random (behaviour at time x, is independent upon behaviour at round x-1). Therefore, in administration units achieving high MDA coverage (receiving drugs) at each treatment round, if there is a high proportion of systematic non-treatment, i.e. the individual's refusing treatment across each round are always the same, referred to as systematically non-treated individuals, then the targeted goal of parasite transmission elimination through reducing community reinfection will be improbable (5). The impact of individual treatment behaviour at each round of MDA delivery is currently unquantified in the literature, but has been suggested as a major hinderance to MDA programmes targeted with transmission elimination (6). Despite being rarely monitored, these longitudinal individual treatment behaviour patterns influenced by demographic, social and geographical factors will directly impact the number of future rounds of MDA required to elimination transmission of the targeted species (7). As such, before donor fatigue and economic pressures reduce the frequency and scale of NTD control programmes, improved monitoring of treatment behaviours to the currently available programmes using clearly defined parameters will be important to measure current successes accurately and comparably, and highlight areas required for intensified efforts to efficiently eliminate transmission of these parasites.

MDA delivery must achieve high compliance at each round for programmatic success. Currently, no guidelines exist, thus the recently published WHO 2030 NTD roadmap (1) would benefit from distinct coverage and compliance targets defined for each parasite species suitable for MDA of PC, as previously highlighted by Krentel *et al.* (2013) (8). As such, longitudinally monitoring of compliance is poorly actioned by the multiple control programmes across the NTD research landscape, as noted by a seminal paper on this topic by Shuford *et al.* (2016) (9). Limited analysis exists documenting age- and gender-stratified demographic factors of treatment

behaviour. Elucidating any such trends in MDA behaviour will enhance the potential of future MDA rounds, for example the targeted dissemination of sensitisation activities to improve compliance in key groups.

Reasons for non-compliance at MDA are commonly reported, whereby MDA participants qualitatively report why they did not participate in MDA; largely divided into reasons for not being reached by a community drug distributor (CDD), or reasons for not swallowing drugs once reached by CDD. The importance this non-treated proportion of the population holds in the context of transmission elimination is dependent upon the R₀ of the disease. If there is a high proportion of non-treatment within a population this is problematic for diseases with a higher R₀ compared to those with a low R₀ as there is more parasite transmission. Albeit a reductionist approach, the population requiring treatment can simply be thought of as R₀-1/ R₀, therefore for R₀ = 2, 50% of the population need to be treated whilst R₀ = 6, 83% of the population need to be treated (10,11).



Parameter	Definition						
Programme reach	The proportion of the eligible population contacted by CDDs during an MDA activity						
Programme reach	(decision point 1).						
Coverage	The proportion of the eligible population contacted by CDDs and receiving the offered						
Coverage	preventative chemotherapy drugs (decision point 2).						
Compliance	The proportion of the eligible population contacted by CDDs and swallowing the						
compliance	offered preventative chemotherapy drugs (decision point 3).						
	The pattern of individual compliance behaviour over consecutive MDA treatment						
Longitudinal compliance	rounds. Patterns can be categorised into systematic treatment, random treatment,						
	and systematic non-treatment.						

Fig 1: Decision tree of MDA treatment behaviour, showing the three behavioural decision points of MDA delivery and their definitions, according to these previously defined parameters by Shuford et al. (2016) (9). Abbreviations: CDD – community drug distributor.

The interaction with CDD and participant can be divided into three key decision points of MDA behaviour, demonstrated in **Fig 1**. Similar decision trees have been published to clarify these parameters (12,13). The three

decision points define the epidemiological parameters, often used interchangeably to the detriment of monitoring and evaluation comparability of control programmes (9). For clarity, in this paper (and in keeping with that described by others (8,9)), the term *coverage* refers to the proportion of the eligible population contacted by CDD, who received the offered drugs. *Compliance*, often confused or conflated with coverage, is referred to in this paper as the proportion of the eligible population who were contacted by CDDs and swallowed the received drugs. The importance of the distinction between these two epidemiological parameters in NTD research was first highlighted by Babu and Babu, 2014, in the context of reaching lymphatic filariasis transmission break in India (14), but has been identified in other disease areas since 1982 (11).

Of crucial importance to control programmes, is the pattern, or lack thereof, of *longitudinal compliance* in individuals. The term longitudinal compliance is defined in this paper as the monitoring of individual treatment behaviour across multiple time points. Preferably, this would be measured by the gold standard of compliance measurement, directly observed treatment (DOT), avoiding any recall bias or desirability bias created from participant's recalling past treatment. Longitudinal compliance is often misconstrued as *repeated cross-sectional compliance*, the repeated measurement of a random sample of the same population whereby individuals missing from different time-points are not removed. By chance, individuals may be sampled multiple times, but as the focus of the measurement at the population-level, not individual, the fine-scale granularity of individual level data is diluted as the parameter measures a broader snapshot of compliance in time. From a longitudinal compliance dataset, individuals who systematically *treated* or *systematically non-treated*, respectively (6,15). The terminology used to describe systematic non-treatment has evolved over recent years, to reflect the agency held by the participant and their behaviour such that systematic non-treatment has previously been referred to as non-adherence, or systematic non-compliance.

Coverage and compliance, if defined at all, are often confused in the literature. High coverage rates can occlude the realities of low drug ingestion (compliance), demonstrating the need for distinct measures. Incongruent denominators and numerators for both parameters are frequently reported, often leading to inappropriate calculations applied for each parameter, requiring careful interpretation of individual studies. Heterogeneity between the population reached, accepting treatment, or swallowing treatment over the eligible, at risk, or total population have all been employed, despite Shuford's review published in 2016 presenting clear definitions for

each parameter and work by Babu and Kar on lymphatic filariasis published in 2004 (16). The lack of consistently defined numerators and denominators for these parameters has been previously noted by Anderson *et al.* (2017) (17). Through deterministic models of parasite transmission and control, Anderson and team demonstrated the relationship between coverage and compliance upon MDA impact and the importance of monitoring these parameters in MDA programmes. Modelling systematic compliance patterns using deterministic and stochastic models, the group showed that, in a low helminth prevalence setting, populations displaying random treatment patterns over multiple rounds of MDA had a larger impact on prevalence decrease than populations displaying systematic non-treatment (18). This is directly relevant to programmes targeted with reaching transmission elimination, as these are inherently situations where low prevalence has been achieved such that a few persistent non-compliers to treatment can sustain transmission.

Improving compliance to treatment will not only increase the number of treated individuals, but these different longitudinal patterns of compliance within populations also influence the transmission dynamics of the parasite (6,18) and thus is crucial to understanding the potential for transmission elimination in a defined population. Intuitively, a systematically non-treated population presents the greatest risk to control programmes compared to those who exhibit random patterns of treatment at each round of MDA. If a high proportion of the population are systematically non-treated (the same people refusing treatment each round), these individuals likely harbour a high proportion of the community parasite burden (parasite reservoir), consistently shedding parasite larvae or eggs into the local environment preventing the targeted goal of elimination of transmission. In areas of poor hygiene and sanitation, it is likely that this contamination from untreated individuals will re-infect the treated population, sustaining transmission (9). In randomly treated populations, individuals will, by definition, have typically received at least one round of treatment given reasonable levels of coverage (>75%), therefore reducing the likelihood that individuals harbour a reservoir of infection. This treatment pattern is therefore favourable, especially in the context of elimination (interruption of transmission), as is the current goal for onchocerciasis, or elimination as a public health problem (targeted for lymphatic filariasis, STH, SCH and trachoma) (1).

For helminth infections in particular, past infection does not confer strong acquired immunity hence, post treatment, all individuals are susceptible to repeated reinfection. Regardless of an individual's previous treatment behaviour, they will become reinfected if they contact infectious eggs or larvae found in the environment. There is a small body of evidence to suggest low levels of immunity develops with age, opposing

7

the argument of age-related exposure to infectious agents, however this factor is not sufficient to counter-act the force of re-infection (19). More substantial research exists to suggest immunity can be acquired for lymphatic filariasis, onchocerciasis, and trachoma infections. The concept of re-infection after treatment is especially important when control programmes cease MDA efforts after a targeted number of rounds or defined high level of coverage is achieved. Unless transmission is completely eliminated, infection in the community will continue from the infectious material surviving in the environment and harboured in untreated people, at a rate defined by the volume of infectious material in the environment - a concept referred to as 'bounce-back' (10). Only when compliance rates (and therefore by virtue, coverage rates) are high enough to reduce the probability of a female worm producing enough transmission stages that go on to survive to reproductive maturity in the human host, to less than unity in value (for all human helminths - STH, schistosomes, filarial worms, and onchocerca) will transmission cease (defined as "transmission break").

Of interest in this paper is how compliance changes over time in populations: the significance of systematic treatment of individuals within a control programme. Historically, the description of demographic patterns, or lack thereof, of systematically non-treated populations over contiguous rounds of MDA has not been well-defined in the literature (9,20). A systematic review of the available data published between the latest well-performed review by Shuford *et al.* (2016) (9) to 2022 was conducted to update the previous review and collect all available compliance data for the five treatable NTDs; STH, schistosomiasis, lymphatic filariasis, onchocerciasis and trachoma. If sufficient data is available, the review will elucidate if systematic non-treatment differed between age, gender, or other identified demographic subset of the population and if these treatment patterns are random or systematic in nature.

Methods

The systematic review was conducted in line with the PRISMA guidelines (21) (**Supporting Information 1**) and is registered with PROSPERO (Registration number: CRD42022301991). Studies detailing systematic non-treatment to MDA for lymphatic filariasis, onchocerciasis, schistosomiasis, STH, and trachoma were searched using a Boolean strategy across PubMed and Web of Science databases in January 2022. The search strategy used and resulting PRISMA workflow are detailed in **Supporting Information 2 and 3**. The original review conducted by Shuford *et al.* (2016) (9) was considered to be completed comprehensively, therefore only studies published from 2016 up to 2022 written in English and Spanish were considered for inclusion. Studies were

screened against minimal inclusion criteria (due to the paucity of relevant studies identified), which were: 1) primary compliance data reported from community or school-based control programmes targeting lymphatic filariasis, onchocerciasis, schistosomiasis, STH, and trachoma infections, 2) at least two defined time points of reported data, and 3) sufficiently large population sample (>100 participants). Where reported, reasons given for non-treatment were collected for subsequent meta-analysis. Care was taken to ensure that all data collected was explicitly defined as compliance (swallowing of drugs). Data described as parameters other than compliance, but using the correct compliance calculation were also recorded, with the variation of parameter definitions noted for later analysis. Nomenclature variations used to describe compliance included "programme / epidemiological coverage", "uptake", and "adherence", as previously noted by Shuford *et al.* (2016) (9).

The 3649 studies generated from the three databases and associated searches were amalgamated in Excel, and de-duplicated based upon DOI and title matches. The 2529 remaining studies were then transferred to Rayyan, an online software using natural language processing and machine learning for data evaluation in a collaborative capacity (22). Using this software, whilst blinded, authors (RM, SGR) conducted title and abstract screening for inclusion, categorising paper themes as quantitative (considered for inclusion, (n = 164)), qualitative (n = 40), modelling (n = 45), or not relevant (n = 2280). Any conflicting cases were discussed and resolved on a case-bycase basis. Despite the exclusion of qualitative studies from this analysis, the themes presented in these studies were used to help interpret the resultant data analyses from the review. The 164 studies marked as guantitative for inclusion were read in full and assessed for eligibility for the final stage of data extraction. The references of which were screened to capture any further relevant data, generating one additional article for inclusion. From the 165 studies identified, 89 studies (datasets) were eligible for data extraction. Due to the paucity of papers containing longitudinal individual compliance data, longitudinal papers were further categorised in a tiered format as containing; individual compliance data (recorded by CDD), individual compliance data (self-reported), and repeated cross-sectional compliance data. Datapoints were extracted when the information presented satisfying the extraction criteria was available for detailed stratifications such as age, multiple regions and individual parasite species. Multiple datapoints were also extracted for cases when both coverage and compliance were reported, stratified by age-group, gender, location and, programme year of collection. Data extracted from the 89 studies included the study type, sample type including age and gender stratifications where available, number of studied participants, length of study, geographic identifiers, drugs provided,

definitions of numerator and denominator for reported parameters, terminology used to describe parameters, and reasons for not complying with treatment. The 89 studies marked for inclusion were analysed in R (4.0.3 (2020-10-10) "Bunny-Wunnies Freak Out"), all figures were generated using ggplot2() unless specified.

Results

A total of 165 studies met the inclusion criteria for data extraction (see **Supporting Information 4**). There were 46 papers discarded from the full-text review (including the Shuford *et al.* (2016) paper) namely due to seemingly relevant papers not reporting any compliance data, such as prevalence studies, or data presented in a format ineligible for extraction e.g. averages (n = 25), to reporting secondary data (n= 8), inability to access full-text data (n = 6), targeted treatment studies (n = 3), and reporting on sample sizes smaller than 100 (n = 2). There were 30 studies identified as reporting cross-sectional (n = 7) and longitudinal (n = 23) coverage data. Removing the irrelevant studies, and those reporting only coverage data, left a total of 89 studies to be considered in the analysis, a descriptive overview of which is provided in **Table 1**.

		Cross-sectional	Longitudinal
		(N = 32)	(N = 57)
Sample Population	preSAC	0 (0)	0 (0)
	SAC	8 (25)	6 (11)
	Adults	2 (6)	9 (16)
	Community	22 (69)	38 (67)
	Other	0 (0)	2 (4)
Stratification	Age	12 (38)	13 (23)
	Gender	13 (41)	14 (25)
	Region	18 (56)	22 (39)
Species	STH	9 (28)	9 (16)
	SCH	11 (34)	6 (11)
	Oncho	4 (12)	18 (32)
	LF	16 (50)	29 (51)
	Trachoma	3 (9)	3 (5)

Table 1: Summary overview of the 89 studies included in the analysis split by the temporal format; either cross-sectional or longitudinal data. The full data extraction of the 165 studies is provided in Supporting Information
4. Frequency and percentage of studies falling into each category is shown as "n (%)". Definitions: LF – lymphatic

filariasis, N – number of studies, Oncho – onchocerciasis, preSAC – preschool-aged children, SAC – school-aged children, SAC – school-aged children, SCH – schistosomiasis, STH – soil-transmitted helminths.

Across the 89 included studies, those stratifying compliance data by location were frequent, employed by 56% and 39% of the cross-sectional and longitudinal studies, respectively. Age and gender stratifications were reported by a smaller proportion of studies. Whole communities most frequently formed the sample population, followed by 69% and 67% of cross-sectional and longitudinal studies, respectively. Sample populations categorised as 'other' used non-standard age breakdowns such as 0-14 year-olds, and 2-14 year-olds. The mean (arithmetic) sample size of cross-sectional studies ($\bar{x} = 4965$) was considerably smaller than that of longitudinal studies ($\bar{x} = 1,257,386$). Five of the included longitudinal studies reported compliance in populations ranging from 1-400 million, covering several districts during national control programmes in Myanmar (23), China (24), Sierra Leone (25,26), and the Dominican Republic (27).

Within the 89 studies included in this analysis, 78 studies reported MDA data for a single parasite species. An additional 30 datapoints were generated by 11 studies reporting compliance data for two (n = 10), three (n = 12), and four (n = 8) species together. The total 108 species-specific datapoints from the 89 datasets are shown in **Fig 2**. Overall, 45, 22, 18, 17 and 6 studies reported compliance data for lymphatic filariasis, onchocerciasis, STH, schistosomiasis, and trachoma. Studies focusing solely upon lymphatic filariasis (n = 37) and onchocerciasis (n = 17) were most numerate and were found to be most consistently published between 2016 and 2022 (depicted as orange and yellow points, respectively, in **Fig 2**). Papers solely focused on STH were less so (n = 9) but were the most frequently reported species (n = 3) in combination with schistosomiasis. Trachoma studies were least common (n = 6) and were reported only as a single species, never in combination with other parasites presumably due to different control methods. No trachoma compliance studies have been published since 2019.

From the 89 studies, an additional 11 geographical datapoints were generated from four studies reporting data from multiple countries, providing a total of 96 geographic datapoints. Globally, studies reporting compliance from Tanzania (n = 11) and Ethiopia (n = 9) were most prevalent, as depicted in **Fig 3**.




Fig 2: Number of studies published each year for each species, from 2016 to 2022. 11 studies are represented as 30 datapoints where studies reported data for more than one species, totalling 96 datapoints from 89 studies. Points are coloured by each of the five reported species. Point shape is defined by the type of data presented, ranked in order of quality: 1 – individual longitudinal compliance, 2 – both longitudinal and cross-sectional compliance, 3 - repeated cross-sectional compliance, 4 - cross-sectional compliance, 5 – undefined cross-sectional. Definitions: LF – lymphatic filariasis, Oncho – onchocerciasis, SCH – schistosomiasis, STH – soil-transmitted helminths.






Fig 3: Choropleth map of studies published globally from 2016 to 2022. Countries where no papers were published are shown in grey. Four studies are represented as 11 datapoints where studies reported data for more than one country, totalling 108 datapoints from 89 studies.

Due to the paucity of available literature detailing individual longitudinal compliance, a hierarchy of studies was created, encompassing both longitudinal and cross-sectional studies as detailed in Table 2. Often, compliance was misconstrued as coverage, and the terminology, numerator, and denominators used to describe these parameters were heterogeneous, as previously noted by Shuford et al. (2016) (9). The reported numerator, denominator, and definitional calculations were carefully analysed for all studies where provided, and the correct parameter was assigned to the data where necessary.

Compliance Data Type	Study Type	Description						
Individual – annually	Cohort, randomised	Longitudinal, individually linked, compliance data across >2 time						
surveyed (n = 3)	controlled trial	points. Recorded during annual surveys either by CDD (directly						
		observed treatment), or self-reported by participant. Focus: individual						
		level.						
Individual – self-	Cross-sectional	onal Longitudinal compliance data over defined/undefined time-period.						
reported (time-specific		Self-reported compliance by an individual at one time-point, looking						
or overall) summary		back in time e.g., self-reported compliance to 5 available MDA rounds.						
(n = 22)		Focus: individual level.						
Repeated cross-	Cross-sectional	Compliance data at each round of MDA for a set cohort (e.g., village or						
sectional (n = 32)		district), repeatedly surveyed over several time points population						
		repeatedly sampled. Individuals not consistently present across all						
		time points are not removed. Focus: population level.						

Cross-sectional (n = 32)Cross-sectionalCompliance data for a single round of MDA. Focus: population level.Table 2: Data type and definition used to classify compliance papers included in the analysis. Longitudinalcompliance data was reported by both longitudinal studies (cohort, randomised controlled trials) and cross-sectional studies.

Of the 89 studies, 57 (64%) contained longitudinal data which were further categorised as individual data (recorded by data collectors or self-reported), repeated cross-sectional data, or cross-sectional data (**Table 2**). The length of studies ranged from repeated cross-sectional compliance from 26 annual rounds of MDA in China (24), to repeated cross-sectional compliance from two biannual rounds in South Sudan (28) and Nigeria (29). There were 30 studies (36%) detailing cross-sectional (single time-point) compliance data, which were further categorised by the numerator and denominator provided. Studies not explicitly defining either of these values were considered "assumed".

The compliance data type reported did not change significantly over time, as shown in **Fig 2**. Repeated crosssectional studies were the most frequent study type, reported in 32 of the 89 studies, preceded by crosssectional compliance (n = 27), both longitudinal and cross-sectional compliance (n = 13), individual longitudinal compliance (n = 12), and undefined cross-sectional compliance (n = 5). Studies reporting individual longitudinal compliance did slightly increase over time (navy bar), with four studies reported in 2021. Similarly, the number of cross-sectional compliance studies published also slightly increased (orange bar), with seven studies reported in 2021.

Incongruent parameter definitions

Not all studies provided clear definitions of the parameter reporting compliance. Analysing the numerators and denominators provided, just 26 (29%) studies could be confidently identified as containing either cross-sectional or longitudinal compliance data; the proportion of the eligible population who were contacted by CDDs and swallowed the offered drugs. Compliance data defining either the correct numerator or denominator for compliance, not both, were categorised as assumed (n = 12). Due to the wide variety of definitions used for the same parameter across studies (see **Fig 5**), studies that did not define either numerator or denominator for the parameter given were classified as undefined (n = 5). These parameters were "epidemiological coverage", "MDA participation", "treatment coverage", "MDA coverage" and "compliance".

The parameter "treatment coverage" (n = 4) was used most frequently to describe cross-sectional compliance, whereas longitudinal compliance was most frequently, correctly referred to as "compliance" (n = 8). Compliance was only correctly used in three of the 32 cross-sectional studies, with the numerator and denominator clearly defined (13,30,31). The variety of parameters provided to describe cross-sectional and longitudinal compliance as defined in this review is shown in **Fig 5**.




Fig 5: The variety of parameters used to describe cross-sectional and longitudinal compliance demonstrated, showing the most frequently used parameters both correctly and incorrectly used to describe compliance. The frequency of parameter use is proportional to the size of the circle. Compliance is used most frequently to describe longitudinal compliance (n = 8), whereas treatment coverage was most frequently used to describe cross-sectional compliance (n = 4). The number of circles represent the number of parameters given for compliance. Figure hand-drawn by authors.

Individual longitudinal compliance data

Longitudinally following cohorts to identify individual patterns of treatment behaviour, and the frequency of each pattern in the population is essential, as previously described. The 57 longitudinal compliance studies were further broken down into three hierarchical categories as detailed previously in **Table 2 (rows 1-3)**, into

individually-linked compliance data recorded at each round (the category originally desired for the review due to the data importance for MDA monitoring and evaluation), compliance data recorded retrospectively (individuals recalling treatment compliance over number of rounds or 'ever' complying to MDA rounds), or repeated cross-sectional compliance data. A sample of the extracted columns from the review is shown below for the 12 studies containing both annually surveyed and self-reported individual compliance data in **Table 3**.

Author	Compliance type	Stratification	Species	Drug	Country	N	Sample Type	Terminology Used	True Definition	Numerator	Denominator
Oswald et al. (2020) (20)	Individual: 4 biannual rounds over 2 years - recorded by CDDs.	Age, gender	STH	ALB	Kenya	36327	whole community	Systematic treatment	Longitudinal compliance	Eligible participants swallowing	Eligible population
Campillo et al. (2021) (32)	Individual: 8 biannual rounds. Self- reported compliance to previous round at each subsequent round.	-	LF	ALB	Republic of Congo, Democratic Republic of the Congo	2658	whole community	Adherence	Assumed longitudinal compliance	Not given	Not given
Liu et al. (2017 (33)	Individual: 2 biannual rounds. Self- reported at each time point.	-	STH	ALB	China	10000	SAC	Taking treatment	Assumed longitudinal compliance	Not given	Eligible population
Tilahun et al. (2018) (34)	Individual - as previously taken: 6 annual rounds. Self-reported compliance at each round.	Age, gender	Trach	AZT	Ethiopia	5826	whole community	Coverage	Longitudinal compliance	Eligible participants swallowing	Eligible population
Osue (2017) (35)	Individual - as previously taken: 10 annual rounds. Self-reported compliance to each round.	Location	Oncho	IVM	Nigeria	438	adults	Taking treatment	Assumed longitudinal compliance	Not given	Not given
Wanji et al. (2018) (36)	Individual - as ever taken: Self- reported compliance to 1-11+ annual rounds.	Age, gender, location	Oncho	IVM	Cameroon	3684	whole community	Ever treated / MDA adherence	Assumed longitudinal compliance	Not given	Eligible population
Manyeh et al. (2020) (37)	Individual - as ever taken: Self- reported. No limit given.	Location	LF	IVM, ALB	Ghana	446	adults	Compliance	Longitudinal compliance	Eligible participants swallowing	Eligible population
Minetti et al. (2019) (38)	<u>Individual - as ever taken:</u> Self- reported. (Maximum median rounds – 8)	Location	LF	-	Ghana	924	adults	Ever treated / MDA adherence	Assumed longitudinal compliance	Not given	Not given
Manyeh et al. (2021) (39)	Individual - as ever taken: Self- reported. Pre- and post- intervention.	-	LF	-	Ghana	446	whole community	Ever taken	Assumed compliance	Not given	Not given
Aza'ah et al. (2020) (40)	Individual - as ever taken: Self- reported, over 5 years.	Age, gender	Oncho	IVM	Cameroon	603	whole community	Compliance	Longitudinal compliance	Eligible participants swallowing	Eligible population

Forrer et al.	Individual - as ever taken:	Age	Oncho	IVM	Cameroon	19915	whole	Adherence	Assumed	Not given	Eligible
(2021)	Categorised into never, 0-50%, 50-						community		longitudinal		population
(41)	75%, 75%+ compliance to possible								compliance		
	rounds.										
Kifle et al.	Individual - as ever taken: 10	Age, gender,	Oncho	IVM	Ethiopia	553	adults	Compliance	Assumed	Not given	Eligible
(2021)	biannual rounds. Self-reported.	location							longitudinal		population
(42)									compliance		

Table 3: A selection of the extracted columns for the 12 studies satisfying the criteria for individual-level data – both annually surveyed by CDD or self-reported by participants (grey shading), and self-reported during a cross-sectional analysis. Available stratifications of compliance data are shown from the possible categories of age, gender, or location. The species targeted for control by MDA, and the drug offered for which compliance to is measured, is also given. The country, and the type and number of participants is also provided. The terminology used to describe compliance is shown, along with the 'true' definition according to this review given the numerator and denominator recorded (where given). Where there are incomplete numerator or denominators provided, compliance can only be assumed given the large heterogeneity of calculations used for the parameter. Abbreviations: ALB – Albendazole, IVM – Ivermectin, LF – Iymphatic filariasis, Oncho – onchocerciasis, SAC – school-aged children, SCH

6 - schistosomiasis, STH - soil-transmitted helminths, Trach - trachoma.

7 A single study was identified as containing annual longitudinal compliance data, referring to the parameter as 8 "systematic treatment". Treatment behaviour of 36,000 individuals' for four rounds of biannual MDA data for 9 STH was recorded by CDDs at point of delivery, digitised, and individually-linked as part of the TUMIKIA project 10 in Kenya (20). A further two studies contained annual assumed longitudinal compliance data, due to incomplete 11 definitions of parameter numerators and denominators, referring to longitudinal compliance as either 12 "treatment adherence" (32), or "taking treatment" (33). In both studies, individuals self-reported their 13 compliance to the previously administered round of MDA, providing data for each round of lymphatic filariasis 14 MDA in the Democratic Republic of the Congo and the Republic of Congo (32), and STH MDA in China (33).

15 Time-specific and overall longitudinal compliance studies were more common (n = 9). Two longitudinal studies 16 asked respondents to recall their previous treatment behaviour at each round, over six annual rounds in Ethiopia 17 for trachoma (34), and over 10 annual rounds in Nigeria for onchocerciasis (35). Three cross-sectional studies 18 asked participants to recall their treatment behaviour during MDA for onchocerciasis over a specific time period, 19 either five annual rounds (40) and 11+ annual rounds (36) in Cameroon, or 10 biannual rounds in Ethiopia (42). 20 Two of these studies referred to compliance in line with the definitions considered for this review (40,42). A 21 further two cross-sectional studies asked participants to recall ever being treated during MDA for lymphatic 22 filariasis in Ghana (37,38). One study reported longitudinal compliance as a percentage of the possible rounds 23 per participant based upon eligibility, breaking compliance into 'never', or complying with "<50%", "50-75%", 24 ">75%" of possible rounds of MDA against onchocerciasis in Cameroon (41). One study reported the change in 25 compliance before and after an interventional effort to increase MDA uptake for lymphatic filariasis control in 26 Ghana (39).

A combination of cross-sectional and longitudinal compliance was reported by 13 studies, whereby compliance to a defined (43–50) or undefined (51–55) number of rounds were reported, alongside compliance at the latest round of MDA. Four of these studies defined compliance in line with the definitions considered for this review (45,51–53). Setting a high reporting standard, Osei *et al.* (2022) (53), Oswald *et al.* (2016) (20) and Krentel *et al.* (2016) (55) provided comprehensive demographic and descriptive factors and associations with receiving, and swallowing MDA through bivariate and multivariate logistic regression analysis. This high level of descriptive detail for coverage and compliance was rarely observed in the literature. The research landscape of MDA


34 reporting and its impact on infection levels would greatly benefit from more studies following these detailed

35 study design principles.

- 36 A total of 32 studies reported repeated cross-sectional compliance data over time periods ranging from a year
- 37 of biannual treatment to 26 years of annual treatment. As these datasets follow compliance at a population
- 38 level, this is not considered as individual longitudinal compliance.

39 <u>Study duration of longitudinal studies</u>


- 40 From the 25 longitudinal studies, the majority consisted of studies asking participants how many rounds of MDA
- 41 they swallowed treatment, over their lifetime or a defined period as shown in yellow in **Fig 4**. Annual and biannal
- 42 studies were found at equal frequencies in the review (n = 5). Biannual studies tended to follow fewer rounds
- 43 of MDA, compared to annual studies.





- 45 of rounds (annual, biannual) or the time frame in which participants were "ever treated".
- 46 <u>Compliance versus coverage</u>

47 From the 32 and 57 cross-sectional and longitudinal studies reporting compliance, 41% (n = 13) and 14% (n = 8) 48 reported coverage data alongside compliance data. These 21 studies produced 173 datapoints of comparable 49 coverage and compliance data for different demographic strata, namely age, gender, location, and programme 50 year. Uniquely, Chami et al. (2017) (13) calculated the average marginal effects (AME) for coverage and 51 compliance against a variety of factors. Most commonly, coverage was reported as a proportion of the eligible 52 population (studies = 16, datapoints = 77), but studies also reported the parameter as a raw number (studies = 53 2, datapoints = 11) or as different named parameters such as epidemiological, programme and geographic 54 coverage (studies = 3, datapoints = 85). There was a mean average difference of 4.91% (min: 0%, max: 30.8%) 55 between coverage and compliance figures reported as a proportions. Similarly, there was a 11.9% (min: 7.04%, 56 max: 21.5%) mean average percentage change between the raw data figures reported. A larger discrepancy of 57 17.7% (min: 10.3%, max: 45.9%) was noted between epidemiological / programme coverage, and compliance / 58 geographical coverage. The difference between the two parameters is shown in Fig 5.



Data Type 🔹 cross-sectional 🔹 longitudinal

Fig 5: The difference between coverage and compliance figures reported by 21 studies as either proportions (A),
raw data (B) or other parameters (C). Datapoints are coloured by the study type, either cross-sectional (13
studies, 69 datapoints) or longitudinal (8 studies, 104 datapoints). An average trendline of the reported data is
shown in solid grey. The shaded line represents the conditional mean function using a linear model calculated by

63 the geom_smooth() functionality within the package ggplot2. A guideline through intercept = 0 is shown to

- 64 highlight the discrepancy between the two parameters.
- 65 <u>Stratification and analysis of compliance by demographic and behavioural factors</u>

66 Beyond the greater understanding benefited from considering compliance over coverage on programme impact, 67 stratifying the former by demographic and behaviour factors will provide further information to highlight target 68 groups for enhanced sensitisation and or mobilisation. A total of 28 studies analysed key factors elucidating 69 positive and negative associations influencing compliance in the studied population. Three main methods were 70 employed for the analysis of compliance strata, mainly univariate, bivariate, and multivariate regression 71 (presented as adjusted odds ratios (AOR)), Chi-squared analysis, and proportional breakdowns. Beyond the age, 72 gender and location strata previously mentioned, further analyses were performed against enrolled/non-73 enrolled SAC, highest education level achieved of respondent, socioeconomic status, community type 74 (rural/urban), marital status, occupation, ethnicity, religion, and length of stay in current village location.

75 Compliance increasing with age was noted by 12 studies. Specifically, compliance to treatment increasing with 76 age was reported by Osei et al. (2022) (53) (AOR 4.23 (95% CI: 0.84-21.19), adults aged >58, compared to 18-27 77 year olds), and Chisha et al. (2020) (56) (AOR 1.45 (95% CI: 1.25-1.69), SAC aged 10-14, compared with to 5-78 9 year olds). Aza'ah et al (2020) (57) presented this phenomena via Chi-squared statistics, noting the proportion 79 of age groups complying with MDA increased from 22.6% (95% CI: 16.3–30.4%) of 10-19 year olds, to 60.3% 80 (95% CI: 53.1–67.1%) of participants aged \geq 50 years (χ 2 = 64.1, df = 3, P < 0.0001), as did Minetti et al. (2019) 81 (38), who noted MDA participation increased with age ($\chi 2 = 8.75$, df = 1, p = 0.003). Mirroring this, Kifle and 82 Nigatu (2021) (42) noted low compliance in young age groups, (AOR 0.68 (95% CI: 0.77-1.76) young adults aged 83 15-24 years, compared to >45 year olds). The variety of methods used to present age-related risk-factors with 84 compliance prevents a subsequent meta-analysis to be conducted. Inconsistent conclusions were drawn for 85 gender-related compliance behaviour. Statistical significance was noted for children enrolled in school, 86 compared to those who were not (AOR = 20.90 (95% CI: 17.41-25.08) (56), AOR 2.29 (95% CI: 1.13-4.61) Asfaw 87 et al. (2021) (58)).

Intuitively, consistent treatment behaviour to consecutive rounds of MDA was noted to decrease parasite
 prevalence. Six studies noted an increased odds of compliance based upon previous compliance, the treatment

behaviour of systematic treatment. This phenomenon was presented with differing outlooks, varying between
increased compliance based upon previous compliance (AOR 10.58 (95% CI: 5.78-19.38)) (53), willingness of
future compliance by Tilahun and Fenta (2018) (34) (AOR 5.78 (95% CI:2.44–13.68)), and non-compliance related
to previous non-compliance reported twice; (AOR 1.620 (95% CI: 1.051-2.497)) (38) and (AOR 9.18 (95% CI: 2.4334.65)) by Dickson et al. (2021) (50). Campillo et al. (2021) (32) further developed the analysis, predicting the
number of subsequent rounds required to clear treatment based upon current compliance to available rounds
of MDA.

97 Aside from demographic factors, perceptions of the MDA activity and the CDD delivering the treatments were 98 also considered by some studies. Common themes included awareness of target disease and the role of MDA, 99 perceived susceptibility to target disease, CDD dedication, health benefits or adverse events related to drug 100 ingestion. Prior knowledge of MDA was noted as significant by two studies, Asfaw et al. (2021) (58) noted a 69% 101 lower compliance to MDA, between prior awareness of date versus date and location of MDA activity (AOR 0.31 102 (95% CI: 0.12–0.82)), whilst Krentel et al. (2016) (55) noted compliance increasing with prior awareness of MDA 103 activity (AOR 2.59 (95% CI: 1.0-6.7)). The perception of drugs to be beneficial to participants was also noted to 104 be significantly associated with increased compliance; (AOR 7.33 (95% CI: 4.13–13.02)) (34), (AOR 5.25 (95% CI: 105 2.55-10.82)) (53), and (AOR 10.74 (95% CI: 5.1-22.6)) (55). The perceived dedication and attitude of CDDs, as 106 well as the protocols of height measurement were analysed by some authors, proving to be significant factors 107 in increasing participant compliance. Travel time to the MDA distribution site was only collected by one study, delineating an individual's will to take MDA, with the practicality of doing so (AOR 0.22 (95% CI: 0.14–0.35) >60 108 109 minutes, AOR 0.08 (95% CI: 0.04–0.17) 30–60 minutes), reference: < 30 minutes) (58). Participant 110 comprehension of parasitic disease (AOR 13.68 (95% CI: 1.65–113.57)) (59), or the purpose of MDA (AOR 2.27 111 (95% CI: 1.44–3.59)) (58) was noted to be significant. Similarly, internal cues to action such as the assumption of 112 own infection status, susceptibility of disease and fear of disease was shown to be significant (AOR 3.628 (95% 113 CI: 1.96–6.73)) (60). It must be noted however, that despite these large AOR presented throughout the literature, 114 the associated confidence intervals are very wide, reducing the reliability of this reported statistic.

115 Discussion

This review highlights the paucity of individual longitudinal compliance studies available in the literature, despite publications dating back to 2004 (16), and more recently by Shuford *et al.* (2016), detailing the need for increased

individual longitudinal cohort based compliance monitoring and reporting in the body of NTD research. The review aimed to compare reported individual longitudinal compliance recorded by CDD, referred to as DOT. The lack of publications resulted in the broadening of inclusion criteria to include all papers reporting compliance at all, analysing the few individual longitudinal studies, with longitudinal compliance self-reported by participants, and both repeated- and cross-sectional compliance studies.

123 This review also reports a large difference between coverage (receiving treatment) to compliance (swallowing 124 treatment) when comparing the data reported (or aligning data reported to the definitions used in this review) 125 by studies, mirroring the 22% coverage-compliance gap previously published by Babu et al. (2014) (14) and the 126 12.1% gap reported by Sitikantha et al. (2019) (61). In practice, this highlights the fact that a significant 127 proportion of individuals that are un-treated are considered within the parameter of coverage. As such, 128 programmes targeted with reaching coverage-based targets, conflating this parameter with compliance, could 129 result in the premature cessation of programme efforts (55). For example, if coverage reaches a defined target 130 e.g. 75% of SAC, and compliance is only 80%, then for a population of 1000, 750 will have received treatment, 131 but only 600 will have swallowed treatment. This assumes the treatment has a 100% efficacy against the 132 parasite, which is not always the case. For instance, albendazole is distributed in STH endemic areas, yet has a 133 range of efficacies for different species, from Ascaris lumbricoides (91.4%), to Trichuris trichiura (50.0%) (62). As 134 such, it may be demoralising when high coverage rates do not translate into efficient control with associated 135 declines in infection prevalence and intensity. Beyond the clear definition of parameters used, a stipulation from 136 WHO to routinely report compliance alongside coverage would be very beneficial. Control programmes targeted 137 with reaching elimination of transmission that neglect to report compliance will be hindered in their monitoring 138 accuracy if compliance is not recorded accurately.

Currently, there is heterogeneity between parameters and their definitions across species-specific guidelines provided by WHO. For example, in the case of lymphatic filariasis control, drug coverage is defined as the proportion of the *eligible* (also referred to as targeted) population that *swallow* drugs. However, in the same guideline, the programmatic drug coverage (defined as the proportion of the *total* population swallowing drugs) is recommended to reach 80%. Two different denominators are defined for the coverage parameter. Drug coverage surveys are also suggested whereby a sub-sample of the population are questioned on their treatment behaviour, including coverage and compliance treatment behaviours (63).This is the first instance of the notion

146 to record compliance in NTD research. Concurrently, guidance provided for STH control defines coverage as the 147 proportion of the target population reached (64). Systematic non-treatment (referred to as systematic non-148 compliance) is mentioned in the context of lymphatic filariasis control, defined as the individuals who never 149 ingest the medicines in any MDA round, but is absent from the analogous STH control guide. It would be 150 beneficial for future editions of the WHO roadmap, and species-specific control guidelines, to clearly delineate 151 between coverage and compliance parameters, as current editions are non-comparable between species. These 152 definitions need to be adopted by WHO across all NTD infections. The mis-match of parameter definitions 153 currently provided by WHO will be particularly problematic for the species recently targeted for integrated 154 control, as these will need to be adhered to across research groups and programmes for synchronous and 155 efficient monitoring and evaluation. The recommendations provided by these guides resonate through the 156 literature. As such, the continued misclassification of MDA parameter definitions in NTD research is highlighted 157 by this review despite the advice presented by Shuford et al. (2016) six years previously (9). At a minimum, 158 regardless of the parameter used by different studies and programmes, the calculation should be clearly defined 159 within the methods enabling the scientific audience to interpret the data unambiguously. In the future, it is 160 hoped that WHO guidelines will align on these parameters, setting the standard of clear definitions for the 161 research community.

162 Since the publication of the last WHO NTD roadmap, considerable progress has been made globally in reducing 163 the number of people infected with NTDs. As an increasing number of endemic communities are recording low 164 prevalence, and the elimination of certain species as a public health problem has been achieved, completed by 165 17 countries for lymphatic filariasis and 10 countries for trachoma (1), a number of countries and regions can 166 realistically look toward elimination of transmission. As previously noted by multiple authors, low parasite 167 prevalence should first be validated with corresponding intensity measures, as commonly employed diagnostic 168 techniques such as Kato Katz for the detection of intestinal nematode eggs in faeces show decreasing sensitivity 169 in low prevalence settings, requiring more expensive, molecular methods (65). Furthermore, as is increasingly 170 noted throughout the literature, to reach elimination of transmission, MDA delivery protocols would benefit 171 from expanding school-based distribution to community-based distribution, as multiple studies have modelled 172 and reported that only employing the former will leave pockets of infection in adults or preSAC who will 173 continually reinfect the treated school aged children, resulting in the targeted communities to require indefinite

25

treatment rounds as re-infection reverses treatment efforts (2,19,66). The coverage goal of this expanded protocol should be either increased to levels superseding that required for coverage to account for the reduced number of individuals swallowing treatment once reached, (the coverage-compliance gap), or include explicit compliance monitoring alongside coverage.

178 The importance of monitoring compliance at the individual level has been previously noted (18), and the impact 179 of longitudinal compliance patterns upon control programme outcome is clear. Hardwick et al. (2021) created a 180 framework of compliance (referred to as 'adherence'), proposing the parameter ω_n to measure the strength of 181 association of previous compliance behaviour at MDA with that of a future round of MDA using stochastic 182 individual-based simulations (7). This uses the notion of conditional probability, whereby the behaviour of an 183 individual at one round of MDA is not independent of their behaviour at a previous round (systematic 184 behaviour). Applying this framework to the age and gender-stratified compliance dataset collected by TUMIKIA 185 across four biannual rounds of MDA, showed that despite high coverage figures, past behaviour-dependent 186 compliance (or non-compliance) lowered the potential of hookworm elimination by 43% and 23% in two 187 surveyed communities, respectively, compared to predictions based upon random compliance (behaviour at 188 one round independent of behaviour at previous round) at each round of MDA. Past behaviour-dependent 189 compliance was particularly apparent in males aged >30 years old. This conditional probability model 190 demonstrates the impact that not only compliance, but demographic factors have upon reaching the goal of 191 elimination of transmission. Of the 89 studies included in this review, compliance stratified by location, gender, 192 and age were rarely provided. The importance of these descriptive strata is disproportional to their frequency. 193 Presenting compliance data as a whole will potentially aggregate important behavioural heterogeneities within 194 communities which need programmatic attention. Future WHO guidelines to Ministries of Health would benefit 195 from not only including coverage stratifications by age and gender, but to reflect this in compliance reporting. 196 MDA behavioural treatment patterns greatly impact MDA success, and thus will further impact the number of 197 required rounds of MDA, and the magnitude of targeted coverage (to account for compliance behaviour).

198 NTD research is sometimes hindered by small budgets and limited study duration, thus the high cost of reporting 199 infrastructure necessary for accurately monitoring individuals over several time points to capture longitudinal 200 compliance may not be realistic. This is reflected in the proportion of longitudinally recorded compliance studies 201 (n = 3) versus cross-sectional surveys using participant recollection (n = 22). As such, cross-sectional surveys

202 conducted on a sub-sample of the treated population who are asked to recall if they have ever been treated, or 203 preferably, how many treatment rounds they have participated in, is more realistic for most resource poor 204 settings. Despite the decrease in accuracy of subject recall compared to DOT recorded by CDDs (which is also 205 subject to its own biases), a cross-sectional snapshot of compliance in the population will provide a 206 complementary measure to coverage and will help elucidate the impact of an MDA activity upon the local 207 parasite burden. Furthermore, such programmes failing to reach targeted prevalence and intensity levels can 208 accordingly target the demographic groups recorded with low compliance, as these fractions will arguably 209 contain a high fraction of the total parasite population in a defined human community.

210 This review identified a single study reporting individual longitudinal compliance (20). This study also presented 211 associations of key demographic and behaviour factors with compliance. Future studies and control programmes 212 monitoring MDA activities, especially those in low prevalence settings, would be wise to follow this example. 213 There are few such longitudinal studies currently underway which follow their study population at an individual 214 level, namely the Geshiyaro project (67) and DeWorm3 (68), both following STH. These studies will have the 215 potential to employ the recommended MDA monitoring strategies and provide individual longitudinal 216 compliance data to the currently sparse pool of literature on the topic. Of most importance, is the inclusion of 217 individual longitudinal compliance recorded by DOT. This is considered the gold standard of reporting in other 218 disease fields that routinely follows longitudinal compliance such as HIV and TB treatment. Despite recently 219 gaining attention in the NTD world, the monitoring of longitudinal compliance and treatment patterns across 220 MDA rounds is well observed across other infectious and non-communicable diseases such as that to HIV 221 treatment (69) and ACE inhibitors (70). The critical importance that systematic treatment patterns of 222 longitudinal compliance impinges upon disease control has led to the development of Medication Event 223 Monitoring System (MEMS), an electronic sensor embedded within medication bottle caps used to track 224 compliance (71). This monitoring system is implemented for patients taking medication for a range of disease 225 pathologies such as bipolar disease (72) and schizophrenia (73), to ulcerative colitis (74). Lessons learnt from 226 other such areas of public health are of high relevance to NTD control programmes.

227 <u>Conclusions</u>

There is a great lack of individual longitudinal compliance monitoring of MDA treatment in the NTD research
landscape. This review has shown that there has been a slight, but steady, increase in the number of papers

27

230 published which contain clearly defined compliance measurements, from a very low baseline. In the future, it is 231 hoped that this trend continues, but at a much greater rate given the importance of these patterns to MDA 232 impact on parasite prevalence and intensity. It must be noted, however, that the individual monitoring of 233 compliance is financially and temporally expensive since it requires longitudinal cohort studies. In addition to 234 enhanced accuracy of coverage and compliance recording required, a greater focus is also required on recording 235 demographic variables such as population size and age structure. Ideally, a census or register of all participants 236 must first be taken to monitor MDA behavioural patterns. As such, prospective cross-sectional studies 237 interviewing participants on their treatment history at one point in time are proving to be the most popular 238 approach. Despite this not being the gold standard of longitudinal compliance measurement, the information 239 that a control programme or local ministry of health will garner, such as the definition of systematic or random 240 compliance patterns in defined demographic sub-groups, will be crucial for guiding future MDA rounds to reach 241 the goals of taking infection to very low levels or indeed eliminating transmission in defined populations or 242 regions. Greater attention by WHO is required to unify definitions on both coverage and compliance, and 243 guidance for the broad range of NTDs that are controlled by MDA programmes.

244 Acknowledgements

The Geshiyaro Project is funded by the Children's Investment Fund Foundation (CIFF), grant number: R-180502741. The authors declare no competing interests.

247 References

2481.WHO. Ending the neglect to attain the Sustainable Development Goals: a road map for neglected tropical249diseases2021–2030.Geneva:WorldHealthOrganization250(https://www.who.int/neglected_diseases/Revised-DraftNTD-Roadmap-23Apr2020.pdf).World Health251Organization. 2020. 196 p.

- Anderson R, Truscott J, Hollingsworth TD. The coverage and frequency of mass drug administration
 required to eliminate persistent transmission of soil-transmitted helminths. Philos Trans R Soc B Biol Sci.
 2014 Jun 19;369(1645).
- Farrell SH, Anderson RM. Helminth lifespan interacts with noncompliance in reducing the effectiveness
 of anthelmintic treatment. PARASITES \& VECTORS. 2018 Jan;11.

28

- 4. World Health Organisation. LONDON DECLARATION ON NEGLECTED TROPICAL DISEASES [Internet].
- 258 World Health Organisation. 2012 [cited 2022 Feb 17]. Available from: 259 https://www.who.int/neglected diseases/London Declaration NTDs.pdf
- Werkman M, Wright JE, Truscott JE, Oswald WE, Halliday KE, Papaiakovou M, et al. The impact of
 community-wide, mass drug administration on aggregation of soil-transmitted helminth infection in
 human host populations. Parasites and Vectors. 2020 Jun 8;13(1):1–12.
- Farrell SH, Truscott JE, Anderson RM. The importance of patient compliance in repeated rounds of mass
 drug administration (MDA) for the elimination of intestinal helminth transmission. Parasit Vectors. 2017
 Jun 12;10(1):1–12.
- 7. Hardwick RJ, Truscott JE, Oswald WE, Werkman M, Halliday KE, Pullan RL, et al. Individual adherence to
 mass drug administration in neglected tropical disease control: A probability model conditional on past
 behaviour. PLoS Negl Trop Dis. 2021 Jan;15(1).
- Krentel A, Fischer PU, Weil GJ. A Review of Factors That Influence Individual Compliance with Mass Drug
 Administration for Elimination of Lymphatic Filariasis. PLoS Negl Trop Dis. 2013 Nov;7(11).
- Shuford K V., Turner HC, Anderson RM. Compliance with anthelmintic treatment in the neglected
 tropical diseases control programmes: A systematic review. Parasites and Vectors. 2016 Jan 27;9(1):1–
 16.
- 274 10. Anderson RM, May RM. Helminth Infections of Humans: Mathematical Models, Population Dynamics,
 275 and Control. Adv Parasitol. 1985 Jan 1;24(C):1–101.
- 276 11. Anderson RM, May RM. Population dynamics of human helminth infections: control by chemotherapy.
 277 Vol. 297, Nature. 1982.
- Willis GA, Mayfield H, Kearns T, Naseri T, Thomsen R, Gass K, et al. A community survey of coverage and
 adverse events following country-wide triple-drug mass drug administration for lymphatic filariasis
 elimination, Samoa 2018. PLoS Negl Trop Dis. 2020 Nov;14(11).
- Chami GF, Kontoleon AA, Bulte E, Fenwick A, Kabatereine NB, Tukahebwa EM, et al. Community-directed
 mass drug administration is undermined by status seeking in friendship networks and inadequate trust

in health advice networks. Soc Sci \& Med. 2017 Jun;183:37–47.

- 14. Babu B V., Babu GR. Coverage of, and compliance with, mass drug administration under the programme
 to eliminate lymphatic filariasis in India: a systematic review. Trans R Soc Trop Med Hyg. 2014 Sep
 1;108(9, SI):538–49.
- Brieger WR, Okeibunor JC, Abiose AO, Ndyomugyenyi R, Wanji S, Elhassan E, et al. Characteristics of
 persons who complied with and failed to comply with annual ivermectin treatment. Trop Med \& Int
 Heal. 2012 Jul 1;17(7):920–30.
- Babu B, Kar SK. Coverage, compliance and some operational issues of mass drug administration during
 the programme to eliminate lymphatic filariasis in Orissa, India. Trop Med \& Int Heal. 2004
 Jun;9(6):702–9.
- Anderson R, Farrell S, Turner H, Walson J, Donnelly CA, Truscott J. Assessing the interruption of the
 transmission of human helminths with mass drug administration alone: optimizing the design of cluster
 randomized trials. Parasit Vectors. 2017 Feb;10.
- 18. Dyson L, Stolk WA, Farrell SH, Hollingsworth TDD. Measuring and modelling the effects of systematic
 non-adherence to mass drug administration. Epidemics. 2017 Mar 1;18:56–66.
- Truscott JE, Hollingsworth TD, Brooker SJ, Anderson RM. Can chemotherapy alone eliminate the
 transmission of soil transmitted helminths? Parasites Vectors 2014 71. 2014 Jun 10;7(1):1–8.
- Oswald WE, Kepha S, Halliday KE, Mcharo C, Safari T, Witek-McManus S, et al. Patterns of individual non treatment during multiple rounds of mass drug administration for control of soil-transmitted helminths
 in the TUMIKIA trial, Kenya: a secondary longitudinal analysis. Lancet Glob Heal. 2020 Nov
 1;8(11):e1418–26.
- 304 21. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta 305 analyses: The PRISMA statement. Int J Surg. 2010 Jan 1;8(5):336–41.
- 306 22. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic
 307 reviews. Syst Rev. 2016 Dec 5;5(1):1–10.

30

- 308 23. Aye NN, Lin Z, Lon KN, Linn NYY, Nwe TW, Mon KM, et al. Mapping and modelling the impact of mass
- drug adminstration on filariasis prevalence in Myanmar. Infect Dis Poverty. 2018 May 31;7(1):1–11.
- 310 24. Mao FZ, Chen YY, Xu XZ, Ni BX, Jin XL, Dai Y, et al. Multi-intervention integrated deworming strategy for
- sustained control of soil-transmitted helminths infections: a case study in Jiangsu Province, China. Infect
 Dis Poverty. 2021 Dec 1;10(1).
- Koroma JB, Sesay S, Conteh A, Paye J, Bah M, Sonnie M, et al. Progress on elimination of lymphatic
 filariasis in Sierra Leone. Parasites and Vectors. 2018 Jun 4;11(1):1–10.
- Koroma JB, Sesay S, Conteh A, Koudou B, Paye J, Bah M, et al. Impact of five annual rounds of mass drug
 administration with ivermectin on onchocerciasis in Sierra Leone. Infect Dis Poverty. 2018 Apr 6;7(1):1–
- 317 12.
- Gonzales M, Noland GS, Mariano EF, Blount S. Lymphatic filariasis elimination in the Dominican Republic:
 History, progress, and remaining steps. PLoS Negl Trop Dis. 2021 Aug 1;15(8):e0009590.
- Ortu G, Khan J, Yibi MS, Nimaya IA. Mass drug administration in Central Equatoria, South Sudan: results
 and suggestions for future distributions. Int Health. 2017 Jul 1;9(4):263–6.
- 322 29. Griswold E, Eigege A, Ityonzughul C, Emukah E, Miri ES, Anagbogu I, et al. Evaluation of Treatment
 323 Coverage and Enhanced Mass Drug Administration for Onchocerciasis and Lymphatic Filariasis in Five
 324 Local Government Areas Treating Twice Per Year in Edo State, Nigeria. Am J Trop Med Hyg. 2018 Jun
 325 25;99(2):396–403.
- 326 30. Kulkarni P, Thomas JJ, Dowerah J, Murthy MRN, Ravikumar K. Mass drug administration programme
 327 against lymphatic filariasis-an evaluation of coverage and compliance in a northern Karnataka district,
 328 India. Clin Epidemiol Glob Heal. 2020 Mar;8(1).
- 329 31. Kulkarni P, Dowerah J, Thomas JJ, Murthy MRN, Ravikumar K. Exploring effectiveness of mass drug
 330 administration program against lymphatic filariasis in Raichur district, Karnataka. Int J Heal ALLIED Sci.
 331 2019;8(4):268–72.
- 32. Campillo JT, Awaca-Uvon NP, Missamou F, Tambwe J-P, Kuyangisa-Simuna G, Weil GJ, et al. Results From
 2 Cohort Studies in Central Africa Show That Clearance of Wuchereria bancrofti Infection After Repeated

Rounds of Mass Drug Administration With Albendazole Alone Is Closely Linked to Individual Adherence.

335 Clin Infect Dis. 2021 Jul;73(1):E176–83.

- 33. Liu C, Lu L, Zhang L, Luo R, Sylvia S, Medina A, et al. Effect of Deworming on Indices of Health, Cognition,
- and Education Among Schoolchildren in Rural China: A Cluster-Randomized Controlled Trial. Am J Trop
 Med Hyg. 2017 Jun 7;96(6):1478–89.
- 339 34. Tilahun Z, Fenta TG. Coverage of azithromycin mass treatment for trachoma elimination in Northwestern
 340 Ethiopia: A community based cross-sectional study. BMC Ophthalmol. 2018 Aug 6;18(1):1–9.
- 341 35. Osue HO. Field-Based Evidence of Single and Few Doses of Annual Ivermectin Treatment Efficacy in
 342 Eliminating Skin Microfilaria Load after a Decade of Intervention. Ethiop J Health Sci. 2017 Mar
 343 1;27(2):129–38.
- 344 36. Wanji S, Chounna Ndongmo WP, Fombad FF, Kengne-Ouafo JA, Njouendou AJ, Longang Tchounkeu YF,
 a45 et al. Impact of repeated annual community directed treatment with ivermectin on loiasis parasitological
 indicators in Cameroon: Implications for onchocerciasis and lymphatic filariasis elimination in areas coa46 endemic with Loa loa in Africa. PLoS Negl Trop Dis. 2018 Sep 1;12(9):e0006750.
- 348 37. Manyeh AK, Ibisomi L, Ramaswamy R, Baiden F, Chirwa T. Exploring factors affecting quality
 implementation of lymphatic filariasis mass drug administration in Bole and Central Gonja Districts in
 Northern Ghana. PLoS Negl Trop Dis. 2020 Aug 1;14(8):e0007009.
- 35. Minetti C, Tettevi EJ, Mechan F, Prada JMJM, Idun B, Biritwum N-KK, et al. Elimination within reach: A
 cross-sectional study highlighting the factors that contribute to persistent lymphatic filariasis in eight
 communities in rural Ghana. PLoS Negl Trop Dis. 2019 Jan;13(1):e0006994.
- 354 39. Manyeh AK, Chirwa T, Ramaswamy R, Baiden F, Ibisomi L. Evaluating context-specific evidence-based
 355 quality improvement intervention on lymphatic filariasis mass drug administration in Northern Ghana
 356 using the RE-AIM framework. Trop Med Health. 2021 Feb;49(1).
- 40. Aza'ah RA, Sumo L, Ntonifor NH, Bopda J, Bamou RH, Nana-Djeunga HC. Point prevalence mapping
 reveals hotspot for onchocerciasis transmission in the Ndikinimeki Health District, Centre Region,
 Cameroon. Parasites and Vectors. 2020 Dec 1;13(1):1–8.

- Forrer A, Wanji S, Obie ED, Nji TM, Hamill L, Ozano K, et al. Why onchocerciasis transmission persists
 after 15 annual ivermectin mass drug administrations in South-West Cameroon. BMJ Glob Heal. 2021
 Jan 1;6(1):e003248.
- Kifle B, Nigatu M. Compliance to a Five-Year Biannual Ivermectin Treatment for Onchocerciasis
 Elimination and Its Determinants among Adults in the Bench Maji Zone, Southwest Ethiopia: A
 Community-Based Cross-Sectional Study. J Parasitol Res. 2021 Mar;2021.
- 366 43. Nath TC, Padmawati RS, Murhandarwati EH. Barriers and gaps in utilization and coverage of mass drug
 367 administration program against soil-transmitted helminth infection in Bangladesh: An implementation
 368 research. J Infect Public Health. 2019 Mar 1;12(2):205–12.
- Kamga G-RR, Dissak-Delon FN, Nana-Djeunga HC, Biholong BD, Ghogomu SM, Souopgui J, et al. Audit of
 the community-directed treatment with ivermectin (CDTI) for onchocerciasis and factors associated with
- adherence in three regions of Cameroon. Parasit Vectors. 2018 Jun 19;11(1):1–16.
- 45. Kamga G-RR, Dissak-Delon FN, Nana-Djeunga HC, Biholong BD, Mbigha-Ghogomu S, Souopgui J, et al.
 Still mesoendemic onchocerciasis in two Cameroonian community-directed treatment with ivermectin
- projects despite more than 15 years of mass treatment. Parasit Vectors. 2016 Nov 14;9(1):1–12.
- 375 46. Dickson BFR, Graves PM, Aye NN, Nwe TW, Wai T, Win SS, et al. The prevalence of lymphatic filariasis
 376 infection and disease following six rounds of mass drug administration in Mandalay Region, Myanmar.
 377 PLoS Negl Trop Dis. 2018 Nov 1;12(11).
- Kamga G-RR, Dissak-Delon FN, Nana-Djeunga HC, Biholong BD, Ghogomu SM, Souopgui J, et al.
 Important progress towards elimination of onchocerciasis in the West Region of Cameroon. Parasit
 Vectors. 2017 Aug 3;10(1).
- Jones C, Ngasala B, Derua YA, Tarimo D, Reimer L, Bockarie M, et al. Lymphatic filariasis transmission in
 Rufiji District, southeastern Tanzania: Infection status of the human population and mosquito vectors
 after twelve rounds of mass drug administration 11 Medical and Health Sciences 1117 Public Health and
 Health Services. Parasites and Vectors. 2018 Nov 13;11(1):1–8.
- 49. Coutts SP, King JD, Pa'au M, Fuimaono S, Roth J, King MR, et al. Prevalence and risk factors associated

- with lymphatic filariasis in American Samoa after mass drug administration. Trop Med Health. 2017 Aug
 4;45(1).
- Dickson BFRR, Graves PM, Aye NN, Nwe TW, Wai T, Win SS, et al. Risk factors for lymphatic filariasis and
 mass drug administration non-participation in Mandalay Region, Myanmar. PARASITES \& VECTORS.
 2021 Jan 1;14(1):1–14.
- 391 51. Akinsanya B, Adewale B, Adenusi A, Lawal AdD, Rahman O. Infectivity of Simulium damnosum s.l. and
 392 therapeutic coverage of ivermectin distribution 10 years post treatment around Owena Dam, Ondo
 393 state, Nigeria. Brazilian J Infect Dis. 2019 Nov 1;23(6):410–8.
- 39452.Lupenza ET, Gasarasi DB, Minzi OM. Lymphatic filariasis elimination status: Wuchereria bancrofti395infections in human populations and factors contributing to continued transmission after seven rounds
- of mass drug administration in Masasi District, Tanzania. PLoS One. 2022 Jan 1;17(1):e0262693.
- 397 53. Osei FA, Newton S, Nyanor I, Osei-Yeboah E, Amuzu EX, Mensah NK, et al. Mass drug administration
 398 targeting Onchocerca volvulus in Owabi catchment area in Ashanti Region, Ghana: Determinants of drug
 399 coverage and drug uptake. Parasite Epidemiol Control. 2022 Feb 1;16:e00235.
- 400 54. Dissak-Delon FN, Kamga G-RR, Humblet PC, Robert A, Souopgui J, Kamgno J, et al. Adherence to 401 ivermectin is more associated with perceptions of community directed treatment with ivermectin 402 organization than with onchocerciasis beliefs. PLoS Negl Trop Dis. 2017 Aug 1;11(8).
- Krentel A, Damayanti R, Titaley CR, Suharno N, Bradley M, Lynam T. Improving Coverage and Compliance
 in Mass Drug Administration for the Elimination of LF in Two `Endgame' Districts in Indonesia Using
 Micronarrative Surveys. PLoS Negl Trop Dis. 2016 Nov 3;10(11):e0005027.
- 406 56. Chisha Y, Zerdo Z, Asnakew M, Churko C, Yihune M, Teshome A, et al. Praziquantel treatment coverage
 407 among school age children against Schistosomiasis and associated factors in Ethiopia: a cross-sectional
 408 survey, 2019. BMC Infect Dis. 2020 Nov;20(1):872.
- 409 57. Aza'ah RA, Sumo L, Ntonifor NH, Bopda J, Bamou RH, Nana-Djeunga HC, et al. Point prevalence mapping
 410 reveals hotspot for onchocerciasis transmission in the Ndikinimeki Health District, Centre Region,
 411 Cameroon. Parasit Vectors. 2020 Oct 1;13(1):1–8.

- 412 58. Asfaw MA, Hailu C, Beyene TJ. Evaluating Equity and Coverage in Mass Drug Administration for Soil-
- 413 Transmitted Helminth Infections among School-Age Children in the Hard-to-Reach Setting of Southern
 414 Ethiopia. Pediatr Heal Med Ther. 2021 Jul;12:325.
- 415 59. Annashr NN, Amalia IS, Dinh HTP. Low Knowledge and Unawareness of the Health Promotion as the 416 Determinant Factors in Non-Compliance to the Mass Drug Administration Program. KESMAS-NATIONAL
- 417 PUBLIC Heal J. 2021 Feb;16(1):39–44.
- Widjanarko B, Saraswati LD, Ginandjar P. Perceived threat and benefit toward community compliance
 of filariasis' mass drug administration in Pekalongan district, Indonesia. Risk Manag Healthc Policy.
 2018;11:189–97.
- 421 61. Banerjee S, Bandyopadhyay K, Khan MF, Akkilagunta S, Selvaraj K, Tripathy JP, et al. Coverage of mass
 422 drug administration for elimination of lymphatic filariasis in urban Nagpur, Central India: A mixed
 423 method study. J Fam Med Prim CARE. 2019 Sep;8(9):3009–14.
- 424 62. Vaz Nery S, Qi J, Llewellyn S, Clarke NE, Traub R, Gray DJ, et al. Use of quantitative PCR to assess the
 425 efficacy of albendazole against Necator americanus and Ascaris spp. in Manufahi District, Timor-Leste.
 426 Parasites and Vectors. 2018 Jun 28;11(1):1–7.
- 427 63. World Health Organisation. Monitoring and epidemiological assessment of mass drug administration in
 428 the global program to eliminate lymphatic filariasis: a manual for national elimination programmes.
 429 Geneva; 2011.
- 430 64. World Health Organsiation. Helminth control in school age children: a guide for managers of control
 431 programmes. Geneva; 2011.
- 432 65. Maddren R, Phillips A, Ower A, Landeryou T, Mengistu B, Anjulo U, et al. Soil-transmitted helminths and
 433 schistosome infections in Ethiopia: a systematic review of progress in their control over the past 20
 434 years. Parasit Vectors. 2021 Dec 1;14(1):1–15.
- 435 66. Anderson RM, Turner HC, Truscott JE, Hollingsworth TD, Brooker SJ. Should the Goal for the Treatment
 436 of Soil Transmitted Helminth (STH) Infections Be Changed from Morbidity Control in Children to
 437 Community-Wide Transmission Elimination? PLoS Negl Trop Dis. 2015 Aug;9(8):e0003897.

438	67.	Mekete K, Ower A, Dunn J, Sime H, Tadesse G, Abate E, et al. The Geshiyaro Project: a study protocol for
439		developing a scalable model of interventions for moving towards the interruption of the transmission of
440		soil-transmitted helminths and schistosome infections in the Wolaita zone of Ethiopia. Parasit Vectors.
441		2019 Oct 29;12(1):1–12.

- 442 68. KH Á, SSR A, RM A, R B, I G, KE H, et al. Assessing the feasibility of interrupting the transmission of soil-443 transmitted helminths through mass drug administration: The DeWorm3 cluster randomized trial 444 protocol. 2018 Jan 1;12(1):e0006166.
- 445 69. Ferguson NM, Donnelly CA, Hooper J, Ghani AC, Fraser C, Bartley LM, et al. Adherence to antiretroviral 446 therapy and its impact on clinical outcome in HIV-infected patients. J R Soc Interface. 2005 Jun 28;2:349-63.
- 447
- 448 70. MacFadyen RJ, Struthers AD. The practical assessment of compliance with ACE-inhibitor therapy--a novel 449 approach. J Cardiovasc Pharmacol. 1997 Jan;29(1):119-24.
- 450 71. El Alili M, Vrijens B, Demonceau J, Evers SM, Hiligsmann M. A scoping review of studies comparing the 451 medication event monitoring system (MEMS) with alternative methods for measuring medication 452 adherence. Br J Clin Pharmacol. 2016;82(1):268-79.
- 453 72. Levin J, Sams J, Tatsuoka C CK, M S. Use of automated medication adherence monitoring in bipolar 454 disorder research: Pitfalls, pragmatics, and possibilities. Ther Adv Psychopharmacol. 2015;5(2):76–87.
- 455 73. Diaz E, Levine HB, Sullivan MC, Sernyak MJ, Hawkins KA, Cramer JA, et al. Use of the Medication Event 456 Monitoring System to estimate medication compliance in patients with schizophrenia. J Psychiatry 457 Neurosci. 2001;26(4):325.
- 458 74. Gillespie D, Hood K, Williams A, Stenson R, Probert C, Hawthorne A. The use of the Medication Event 459 Monitoring System (MEMS) for assessing medication adherence for chronic conditions: use and results 460 from a 12 month trial of patients in remission with ulcerative colitis (UC). From Clin Trials Methodol Conf. 461 2011;4-5.
- **Supporting Information Captions** 462
- 463 Supporting Information 1: PRISMA guidelines for full text of review and abstract.

36

medRxiv preprint doi: https://doi.org/10.1101/2022.10.06.22280483; this version posted October 7, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

- **Supporting Information 2**: The search strategy employed to generate the review.
- **Supporting Information 3**: Workflow of screening and inclusion of studies as defined by the PRISMA guidelines.
- **Supporting Information 4**: The complete 89 studies identified as containing compliance data.

467 Supporting Information 1

468 PRISMA guidelines

Section and Topic	ltem #	Checklist item	Location where item is reported
TITLE			
Title	1	Identify the report as a systematic review.	Line 2
ABSTRACT			
Abstract	2	See the PRISMA 2020 for Abstracts checklist.	See page 4
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of existing knowledge.	Line 131- 175
Objectives	4	Provide an explicit statement of the objective(s) or question(s) the review addresses.	Line 176- 184
METHODS			
Eligibility criteria	5	Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses.	Line 191- 196 Line 205- 207 Line 224- 231
Information sources	6	Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted.	Line 187- 189
Search strategy	7	Present the full search strategies for all databases, registers and websites, including any filters and limits used.	SI 2
Selection process	8	Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process.	Line 203- 207
Data collection process	9	Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process.	-
Data items	10a	List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect.	-
	10b	List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information.	Line 218- 222
Study risk of bias	11	Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each	-

Section and Topic	ltem #	Checklist item	Location where item is reported
assessment		study and whether they worked independently, and if applicable, details of automation tools used in the process.	
Effect measures	12	Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results.	Line 193
Synthesis methods	13a	Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)).	Line 205- 207
	13b	Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions.	Line 197- 201
	13c	Describe any methods used to tabulate or visually display results of individual studies and syntheses.	Line 222- 223
	13d	Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used.	-
	13e	Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-regression).	-
	13f	Describe any sensitivity analyses conducted to assess robustness of the synthesized results.	-
Reporting bias assessment	14	Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases).	-
Certainty assessment	15	Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome.	-
RESULTS			
Study selection	16a	Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram.	SI 3
	16b	Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded.	Line 225- 230
Study characteristics	17	Cite each included study and present its characteristics.	Line 327 SI 4
Risk of bias in studies	18	Present assessments of risk of bias for each included study.	-
Results of individual studies	19	For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots.	Table 1, Figure 2, Figure 3
Results of	20a	For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies.	-
syntheses	20b	Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect.	Line 393- 441
	20c	Present results of all investigations of possible causes of heterogeneity among study results.	Throughout

Section and Topic	ltem #	Checklist item	Location where item is reported
			results section
	20d	Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results.	-
Reporting biases	21	Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed.	-
Certainty of evidence	22	Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed.	Line 440- 441
DISCUSSION			
Discussion	23a	Provide a general interpretation of the results in the context of other evidence.	Line 443- 449 Line 505- 524
	23b	Discuss any limitations of the evidence included in the review.	Line 446- 449
	23c	Discuss any limitations of the review processes used.	-
	23d	Discuss implications of the results for practice, policy, and future research.	Line 462- 465 Line 484- 488
OTHER INFORMA	TION		
Registration and	24a	Provide registration information for the review, including register name and registration number, or state that the review was not registered.	Line 187
protocol	24b	Indicate where the review protocol can be accessed, or state that a protocol was not prepared.	Line 191
	24c	Describe and explain any amendments to information provided at registration or in the protocol.	-
Support	25	Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review.	Line 574
Competing interests	26	Declare any competing interests of review authors.	Line 573
Availability of data, code and other materials	27	Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review.	SI 4

From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi: 10.1136/bmj.n71

For more information, visit: <u>http://www.prisma-statement.org/</u>

Section and Topic	ltem #	Checklist item	Reported (Yes/No)
TITLE			
Title	1	Identify the report as a systematic review.	Line 2
BACKGROUND			
Objectives	2	Provide an explicit statement of the main objective(s) or question(s) the review addresses.	Line 19
METHODS			
Eligibility criteria	3	Specify the inclusion and exclusion criteria for the review.	Line 25-26
Information sources	4	Specify the information sources (e.g. databases, registers) used to identify studies and the date when each was last searched.	Line 23
Risk of bias	5	Specify the methods used to assess risk of bias in the included studies.	-
Synthesis of results	6	Specify the methods used to present and synthesise results.	Line 26-27
RESULTS	•		
Included studies	7	Give the total number of included studies and participants and summarise relevant characteristics of studies.	Line 27-28
Synthesis of results	8	Present results for main outcomes, preferably indicating the number of included studies and participants for each. If meta-analysis was done, report the summary estimate and confidence/credible interval. If comparing groups, indicate the direction of the effect (i.e. which group is favoured).	Line 28-29
DISCUSSION			
Limitations of evidence	9	Provide a brief summary of the limitations of the evidence included in the review (e.g. study risk of bias, inconsistency and imprecision).	Line 29
Interpretation	10	Provide a general interpretation of the results and important implications.	Line 29-32
OTHER			
Funding	11	Specify the primary source of funding for the review.	-
Registration	12	Provide the register name and registration number.	Line 24

From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting 478 systematic reviews. BMJ 2021;372:n71. doi: 10.1136/bmj.n71

For more information, visit: <u>http://www.prisma-statement.org/</u>

medRxiv preprint doi: https://doi.org/10.1101/2022.10.06.22280483; this version posted October 7, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

482 Supporting Information 2

483 Search strategy

484

The following search strategy was employed for the review, allowing for minor syntax changesbetween search engines.

487 soil-transmitted helminths" OR helminth* OR Helminthiasis OR ascari* OR hookworm OR trichur* 488 OR strongyl* OR schistosom* bilharz* OR onchocerc* OR "river blindness" OR "elephantiasis" OR "lymphatic filariasis" OR "Wuchereria bancrofti" OR "Brugia malayi" OR wucherer* OR brugia* OR 489 490 ancylostomatoidea OR Ancylostoma OR Necator OR trachoma*) AND ("compliance" OR "non-491 compliance" OR "adherence" OR "non-adherence" OR "refusal" OR "medication adherence" OR "systematic non-treatment" OR "systematic treatment" OR "systematic adherence" OR "systematic 492 compliance" OR "never treated" OR "directly observed treatment" OR "mass drug administration" OR 493 494 "systematic non-compliance" OR "coverage" OR "treatment coverage" OR "surveyed coverage" OR 495 "uptake" OR "participation" 496


- 497 Confined to studies:
- 498 Published from 01/01/2016 01/01/2022
- 499 Written in English or Spanish

500

medRxiv preprint doi: https://doi.org/10.1101/2022.10.06.22280483; this version posted October 7, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

501 Supporting Information 3

502 PRISMA flow diagram



*categorisation of studies was completed using the assistance of artificial intelligence software (AI), Ryann. All
 decisions were manually confirmed by at least two authors.

Title	Ye ar	Journal	Countr y	Region	Noof.par ticipants	Sampl e.Type	Para meter	dataT ype	dataF ormat	Age.Str atified	Gender.S tratified	Multiple. Regions	X.100.Par ticipants	S T H	S C H	L F	On cho	Tr ac h	Rounds. of.MDA	Noof.r ounds	Biannual. or.annual	Drug.Give n	Drug.Dose	Table.NoFigure.with .Compliance.Data	True.defi nition	Given.Nu merator	Given.Den ominator
Lymphatic Filariasis Elimination Status: Wuchereria Bancrofti Infections In Human Populations And Factors Contributing To Contributing Transmissio n After Seven Administrati On In Masasi District, Tanzania	20 22	Plos One	Tanzani a	Masasi	590	adults	compl	longit udinal	both	no	yes	yes	yes	n o	n o	у е s	no	no	Ever taken - no limit given, and previous ly taken	100	E	ALB	400mg	Table 4	longitudinal	and cross-sect	onal
Mass Drug Administrati on Targeting Onchocerca Volvulus In Owabi Catchment Area In Ashanti Region, Ghana: Determinant s of Drug Coverage And Drug Uptake	20 22	Parasite Epidemi ology And Control	Ghana	Ashanti	2008	adults	compl	longit udinal	both	yes	yes	no	yes	n o	no	n o	yes	no	Ever taken - no limit given, and previous ly taken	100	E	ivermectin	NA	Table 3, Table 5	longitudinal compliance	and cross-sect	onal
Opiake Compliance To A Five- Year Biannual Ivermectin Treatment For Onchocercia sis Elimination And Its Determinant s Among Adults In The Bench Maji Zone, Southwest Ethiopia: A Community- Based Cross- Sectional Study	20 21	Journal Of Parasitol Ogy Research	Ethiopi a	Bench Maji Zone	553	adults	compl	longit udinal	indivi dual	yes	уез	уез	yes	n o	n o	n o	yes	no	Ever taken - 10 rounds/ 5 years	10	В	ivermectin	NA	Table 2	assumed longitudi nal compilan ce	not given	eligible population
Coverage Evaluation Surveys Following Soli- Transmitted Helminthiasi s And Schistosomi asis Mass Drug Administrati on In Wolaita Zone Of Ethiopia-The	20 21	Plos One	Ethiopi a	Wolayi ta zone	18875	whole comm unity	compl	cross- sectio nal	compl iance	no	no	yes	yes	y e s	y es	n o	no	no	N/A	NA	NA	ALB, PZQ	400mg ALB (> 2 years old), 10ml syrup of 200 mg per 5ml ALB (1-2 years old), 600mg PZQ (>4 years old) in a height- dose (1-5 tablets)	Table 2 and Table 3	complian ce	eligible participa nts swallowi ng	eligible population

Geshiyaro Project																											
Coverage Validation Survey For Lymphatic Filariasis Treatment In Itang Special District Of Gambella Regional State Of Ethiopia: A Cross- Sectional	20 21	Infection And Drug Resistan ce	Ethiopi a	Gambe Ila	2082	whole comm unity	compl iance	cross- sectio nal	compl iance	yes	yes	no	yes	n o	n o	У e s	no	no	N/A	NA	NA	IVM, ALB	NA	Table 1, 2, 3	complian ce	eligible participa nts swallowi ng	eligible population
Study Evaluating Context- Specific Evidence- Based Quality Improvemen t Intervention On Lymphatic Filariasis Mass Drug Administrati on In Northern Ghana Using	20 21	Tropical Medicine And Health	Ghana	Bole District	446	whole comm unity	compl iance	longit udinal	indivi dual	no	no	no	yes	n o	n o	y e s	no	no	pre and post interven tion	2	8	N/A	NA	Table 4	assumed complian ce	not given	not given
The Re-Aim Framework Evaluating Equity And Coverage In Mass Drug Administrati on For Soil- Transmitted Helminth Infections Among School-Age Children In The Hard- To-Reach Setting Of Southern	20 21	Pediatric Health, Medicine And Therape utics	Ethiopi a	South Omo Zone	956	SAC	compl iance	cross- sectio nal	compl iance	yes	yes	no	yes	y e s	n o	n o	no	no	N/A	NA	NA	ALB, MBD	albendazol e (400 mg) or mebendaz ole (500 mg)	Table 3	complian ce	eligible participa nts swallowi ng	eligible population
Ethiopia Evaluation Of Mass Drug Administrati on For Schistosomi asis And Soil- Transmitted Helminths In School-Aged Children In Bankass, Mali	20 21	Internati onal Journal Of Infectiou S Diseases : Ijid : Official Publicati on Of The Publicati on Of The Society For Infectiou S Diseases	Mali	Bankas s	2128	SAC	undefi ned	cross- sectio nal	undefi ned	no	no	no	yes	y e s	у es	n	no	no	N/A	NA	NA	praziquant el and albendazol e	NA	Table 1	undefine d	not given	not given
Factors Associated With Soil- Transmitted Helminths Infection In	20 21	Diseases Plos Neglecte d Tropical Diseases	Benin	Comé	6139	whole comm unity	compl iance	cross- sectio nal	assum ed compl iance	no	no	no	yes	y e s	n o	n o	no	no	N/A	NA	NA	albendazol e	NA	Table 3 and 4	assumed complian ce	not given	not given

Benin: Findings From The Deworm3 Study																											
Factors Influencing Mass Drug Administrati on Adherence And Community Distributor Opportunity Costs In Liberia: A Mixed- Methods	20 21	Parasites & Vectors	Liberia	Bong and Maryla nd	524	whole comm unity	compl iance	cross- sectio nal	assum ed compl iance	no	yes	yes	yes	n	y es	y e s	yes	no	N/A	NA	NA	ivermectin (IVM), albendazol e (ABD)	NA	Table 3	assumed complian ce	not given	not given
Approach Impact Of Annual Versus Semiannual Mass Drug Administrati on With Ivermetin And Albendazole On Helminth Infections In Southeaster n Liberia	20 21	The America n Journal Of Tropical Medicine And Hygiene	Liberia	Maryla nd County	7838	whole comm unity	compl	longit udinal	RCS	no	no	no	yes	y e s	у es	y e s	yes	no	5 rounds over 72 months - self reported	NA	NA	ivermectin and albendazol e	ivermectin (200mg/kg , dosed using a dosingpole) plus albendazol e (afixed dose of 400 mg)	Table 1	complian ce	eligible participa nts swallowi ng	eligible population
Ivermectin Treatment Coverage Validation In Two Onchocercia sis Endemic Districts In Ethiopia: A Community- Based Cross- Sectional Study, 2019	20 21	Journal Of Multidisc iplinary Healthca re	Ethiopi a	Benish angul- Gumuz and Gambe Ila	3765	whole comm unity	compl iance	cross- sectio nal	compl iance	yes	yes	yes	yes	n	n	n o	yes	no	N/A	NA	NA	ivermectin	NA	Table 3	complian ce	eligible participa nts swallowi ng	eligible population
Low Knowledge And Unawarenes s Of The Health Promotion As The Determinant Factors In Non- Compliance To The Mass Drug Administrati on Program	20 21	Kesmas- National Public Health Journal	Indone sia	Cilimus District , Kuning an	106	whole comm unity	compl	cross- sectio nal	assum ed compl iance	yes	no	no	yes	n	n	y e s	no	no	N/A	NA	NA	MDA, not specificifie d	NA	Table 2	assumed complian ce	eligible participa nts swallowi ng	not given
on Program Lymphatic Filariasis Elimination In The Dominican Republic: History, Progress, And Remaining Steps	20 21	Plos Neglecte d Tropical Diseases	Domini can Republi c	El Seibo, La Altagra cia, District o Nacion al, Bahoru co	1174050	whole comm unity	undefi ned	longit udinal	RCS	no	no	yes	yes	n o	n o	y e s	no	no	5 and 3 rounds of annual MDA	NA	NA	ALB and DEC	NA	Table 1, 3, 4	NA		at risk population
Multi- Intervention Integrated Deworming Strategy For	20 21	Infectiou s Diseases Of Poverty	China	Jiangsu Provinc e	1000000	whole comm unity	compl iance	longit udinal	RCS	no	no	no	yes	y e s	n o	n o	no	no	26 annual rounds fo MDA	NA	NA	MEB, ALB	Mebendaz ole or albendazol e pills (400 or 500 mg)	Figure 2	complian ce	eligible participa nts swallowi ng	eligible population

Sustained Control Of Soil- Transmitted Helminths Infections: A Case Study																			for province								
In Jiangsu Province, China Results From 2 Cohort Studies In Central Central Central Central Central Cearance Of Wuchereria Bancrofti Infection After Repeated Rounds Of Mass Drug Administrati on With Albendazole Alone Is Closely	20 21	Clinical Infectiou S Diseases : An Official Publicati on Of The Infectiou S Diseases Society Of America	Republic o Democrati Republic o Congo	ic	2658	whole comm unity	compl iance	longit udinal	indivi dual	no	no	no	yes	n o	n o	y e s	no	no	8 rounds over 4 years - self reported on complia nce to previous ach round at each round	8	B	Albendazo le	single tablet of ALB (400 mg)	Supplementary Material 1	assumed longitudi nal complian ce	not given	not given
Linked To Individual Adherence Risk Factors For Lymphatic Filariasis And Mass Drug Administrati on Non- Participation In Mandalay Region,	20 21	Parasites & Vectors	Myanm ar	Manda lay Region	1014	whole comm unity	compl iance	longit udinal	both	no	no	no	yes	n o	n o	y e s	no	no	Ever taken - over 6 rounds/ years, taken last round	6	E	DEC and albendazol e	NA	Table 1	assumed cro and longituc compliance	oss-sectional linal	eligible population
Myanmar Why Onchocercia sis Transmissio n Persists After 15 Annual Ivermectin Mass Drug Administrati ons In South-West	20 21	Bmj Global Health	Camer oon	South west	19,915	whole comm unity	compl	longit udinal	indivi dual	yes	no	no	yes	n o	n o	n o	yes	no	ever taken - broken into never, 0- 50%, 50- 75%, 75%+ possible rounds	100	E	Ivermectin	NA	Table 1, Figure 2	assumed longitudi nal complian ce	not given	eligible population
Cameroon A Community Survey Of Coverage And Adverse Events Following Country- Wide Triple- Drug Mass Drug Administrati on For Lymphatic Filariasis Elimination,	20 20	Plos Neglecte d Tropical Diseases	Samoa	All islands	4420	whole comm unity	compl iance	cross- sectio nal	compl iance	no	no	no	yes	n o	n o	y e s	no	no	N/A	NA	NA	IVM, DEC, ALB	ivermectin 150– 2007g/kg, diethylcar bamazine [DEC] 6mg/kg, and albendazol e 400mg	Fig 2, Figure 4, Figure 5	complian ce	eligible participa nts swallowi ng	eligible population
Samoa 2018 Addressing Barriers Of Community Participation And Access	20 20	Plos Neglecte d Tropical Diseases	Kenya	Coastal (Kalole ni sub- county)	688	adults	compl iance	longit udinal	RCS	no	no	no	yes	n o	n o	y e s	no	no	complia nce, and previous ly taken	NA	NA	ALB, DEC	DEC, 6 mg/kg plus albendazol e (400 mg)	Table 6	repeated as compliance	sumed cross-see	tional

To Mass Drug Administrati on For Lymphatic Filariasis Elimination In Coastal Kenya Using A Participatory Approach																											
Exploring Factors Affecting Quality Implementa tion Of Lymphatic Filariasis Mass Drug Administrati on In Bole And Central Gonja Districts In Northern Ghana	20 20	Plos Neglecte d Tropical Diseases	Ghana	Bole and Central Gonja district s	446	adults	compl iance	longit udinal	indivi dual	no	no	yes	yes	n	n o	y e s	no	no	Ever taken - no limit given	100	E	ivermectin and albendazol e	NA	Table 4	longitudi nal complian ce	eligible participa nts swallowi ng	eligible population
Impact Of Annual And Semi-Annual Mass Drug Administrati on For Lymphatic Filariasis And Onchocercia sis On Hookworm Infection In Cote D'ivoire	20 20	Plos Neglecte d Tropical Diseases	lvory Coast	Akoup é and Abeng ourou	2022	whole comm unity	compl iance	longit udinal	RCS	no	no	no	yes	У e s	n	y e s	yes	no	average d	ΝΑ	NA	IVM, ALB	IVM (0.2 mg/kg) and ALB (a fixed dose of 400 mg)	In results text	complian ce	eligible participa nts swallowi ng	eligible population
Lessons Learned In Conducting Mass Drug Administrati on For Schistosomi asis Control And Measuring Coverage In An Operational Research Setting	20 20	The America n Journal Of Tropical Medicine And Hygiene	Kenya, Mozam bique, Tanzani a, Ivory Coast, Niger	Multipl e	350000	whole comm unity	compl iance	longit udinal	RCS	no	no	yes	yes	n o	γ es	n o	no	no	multiple rounds and years and countrie s	NA	NA	Albendazo le and praziquant el	NA	Figure 1, 2, 3, 5, Supp table 1	complian ce	eligible participa nts swallowi ng	eligible population
Lot Quality Assurance Sampling To Assees Coverage And Compliance Following Mass Drug Administrati on To Eliminate Lymphatic Filariasis In Fiji: A Methodolog ical Approach	20 20	Plos One	Fiji	North, Central , Eastern divisio n	304	whole comm unity	compl	cross- sectio nal	compl iance	no	no	yes	yes	n	n	y e s	no	no	N/A	NA	NA	ALB and DEC	albendazol e (one fixed dose of 400 mg) with diethylcar bamazine citrate (DEC, 6 mg/kg body weight)	Table 2	complian ce	eligible participa nts swallowi ng	eligible population
Mass Drug Administrati on Programme Against	20 20	Clinical Epidemi ology And	India	northe rn Karnat aka district	1110	adults	compl iance	cross- sectio nal	compl iance	no	no	yes	yes	n o	n o	y e s	no	no	N/A	NA	NA	DEC, ALB	NA	Tab 1	complian ce	eligible participa nts swallowi ng	eligible population

Lymphatic Filariasis-An Evaluation Of Coverage And Compliance In A Northern Karnataka District, India		Global Health																									
Patterns Of Individual Non- Treatment During Multiple Rounds Of Mass Drug Administrati on For Control Of Soil- Transmitted Helminths In The Tumikia A Secondary Longitudinal Analysis	20 20	The Lancet Global Health	Kenya	Kwale County , Bungo ma County	36327	whole comm unity	compl iance	longit udinal	indivi dual	yes	yes	по	yes	y e s	n o	n o	no	no	4 rounds over 2 years - recorde d by CDD, digitised , and participa nt linked over the 4 rounds	4	A	Albendazo le	400 mg albendazol e	Supplementary Material 1	longitudi nal complian ce	eligible participa nts swallowi ng	eligible population
Point Provalence Mapping Reveals Hotspot For Onchocercia sis Transmissio n In The Ndikinimeki Health District, Centre Region, Cameroon	20 20	Parasites & Vectors	Camer oon	Centre Region	603	whole comm unity	compl iance	longit udinal	indivi dual	yes	yes	no	yes	n o	n	n	yes	no	Ever taken - 5 years	5	E	lvermectin	NA	Data reported in text	longitudi nal complian ce	eligible participa nts swallowi ng	eligible population
Praziquantel Treatment Coverage Among School Age Children Against Schistosomi asis And Associated Factors In Ethiopia: A Cross- Sectional Survey, 2019	20 20	Bmc Infectiou s Diseases	Ethiopi a	Nation al	5679	SAC	compl iance	cross- sectio nal	assum ed compl iance	yes	yes	yes	yes	n o	У es	n o	no	no	N/A	NA	NA	praziquant el	height dependent	Table 2	assumed complian ce	not given	not given
Prevalence And Correlates Of Lymphatic Filariasis Infection And Its Morbidity Following Mass Ivermectin And Albendazole Administrati on In Mikinga District, North-	20 20	Journal Of Clinical Medicine	Tanzani a	Mkinga District	4115	whole comm unity	compl iance	cross- sectio nal	assum ed compl iance	yes	no	yes	yes	n o	n o	γ e s	no	no	N/A	NA	NA	IVM, ALB	NA	Figure 3, Figure 4	assumed complian ce	not given	not given

Eastern Tanzania																											
Preventive Chemothera py Coverage Against Soll- Transmitted Helminth Infection Among School Age Children: Implications From Coverage Validation Survey In Ethiopia,	20 20	Plos One	Ethiopi a	Benish angul- Gumuz and Gambe Ila	8154	SAC	compl	cross- sectio nal	compl iance	yes	yes	yes	yes	У e s	n o	n o	no	no	N/A	NA	NA	ALB, MEB	NA	Figure 1, Table 3	complian ce	eligible participa nts swallowi ng	eligible population
2019 The Usefulness Of Indirect Diagnostic Tests For Schistosoma Haematobiu m Infection After Repeated Rounds Of Mass Treatment With Praziquantel In Mpwapwa And Chakechake Districts In Tanzania	20 20	Internati onal Journal Of Infectiou s i ijid : Official Publicati on Of The Internati onal Society For Infectiou s Diseases	Tanzani a	Mpwa pwa and Chakec hake district S	503	SAC	undefi ned	cross- sectio nal	undefi ned	no	no	yes	no	n	y es	n o	no	no	N/A	NA	NA	PZQ	praziquant el (40 mg/kg)	in the text under Tab 1	undefine d	not given	not given
Barriers And Gaps In Utilization And Coverage Of Mass Drug Administrati on Program Against Soil- Transmitted Helminth Infection In Bangladesh: An Implementa tion Research	20 19	Journal Of Infection And Public Health	Bangla desh	Dhaka and Sylhet	263	SAC	compl	longit udinal	both	no	no	no	yes	у е s	n o	n o	no	no	2 rounds over 1 year - self reported complia nce to possible rounds	2	B	MEB	mebendaz ole (500 mg)	Table 3, Table 4	longitudi nal and cross- sectional complian ce	eligible participa nts swallowi ng	eligible population
Bridging The Gap In Outreach And Compliance With Mass Drug Administrati on For Lymphatic Filariasis Elimination Iin An Endemic District In Kerala, India: An Intervention Research Approach	20 19	Health Educatio n Research	India	Kerala	4861	whole comm unity	compl	longit udinal	RCS	no	no	no	yes	n o	n o	y e s	no	no	pre and post interven tion	NA	NA	ALB and DEC	NA	Table 2	complian ce	eligible part	

Comparison Of Reported And Survey- Based Coverage In Onchocercia sis Programs Over A Period Of 8 Years In Cameroon	20 19	The America n Journal Of Tropical Medicine And Hygiene	Uganda, C	Cameroon	38433	whole comm unity	compl	longit udinal	RCS	no	no	yes	yes	n o	n o	n o	yes	no	8 years of data, multiple regions in each	NA	NA	Ivermectin		Table 2	assumed co	mpliance	eligible population
And Uganda Coverage Assessment Survey Following Trachoma Mass Drug Administrati on (Mda) In Six Districts Of Oromia, Western Ethiopia, 2017	20 19	Plos Neglecte d Tropical Diseases	Ethiopi a	Oromia	1747	whole comm unity	compl	cross- sectio nal	compl	yes	yes	yes	yes	n o	n o	n o	no	ye S	N/A	NA	NA	azithromy cin	NA	Figure 2, 3, 4	complian ce	eligible participa nts swallowi ng	eligible population
Coverage Of Mass Drug Administrati on For Elimination Of Lymphatic Filariasis In Urban Nagpur, Central India: A Mixed Method Study	20 19	Journal Of Family Medicine And Primary Care	India	Nagpur	1096	whole comm unity	compl iance	cross- sectio nal	compl iance	yes	yes	no	yes	n o	n o	y e s	no	no	N/A	NA	NA	ivermectin , albendazol e and DEC	NA	Table 1	complian ce	eligible participa nts swallowi ng	eligible population
Effects, Equity, And Cost Of School- Based And Community- Wide Treatment Strategies For Soil- Transmitted Helminths in Kenya: A Chotrolled Trial	20 19	Lancet (London, England)	Kenya	Kwale	22788	whole comm unity	compl iance	longit udinal	RCS	yes	no	no	yes	y e s	n o	n	no	no	biannual (4 rounds) and annual treatme nt (2 rounds)	NA	NA	ALB	400mg	Table 2	complian ce	eligible participa nts swallowi ng	eligible population
Elimination Within Reach: A Cross- Sectional Study Highlighting The Factors That Contribute To Persistent Lymphatic Filariasis In Eight Communitie S In Rural Ghana	20 19	Plos Neglecte d Tropical Diseases	Ghana	Nzema East district, Ellemb elle district	924	adults	compl	longit udinal	indivi dual	no	no	yes	yes	n o	n o	y e s	no	no	Ever taken - maximu m median rounds - 8	12	A	NA	NA	Fig 2	assumed longitudi nal complian ce	not given	not given
Ghana Exploring Effectivenes s Of Mass Drug Administrati	20 19	Internati onal Journal Of Health	India	Karnat aka	1222	whole comm unity	compl iance	cross- sectio nal	compl iance	no	no	yes	yes	n o	n o	y e s	no	no	N/A	NA	NA	ALB, DEC	NA	Text under tab 1, tab 2	complian ce	eligible participa nts swallowi ng	eligible population

on Program Against Lymphatic Filariasis In Raichur District, Karnataka		And Allied Sciences																									
Improved Assessment Of Mass Drug Administrati on And Health District Managemen t Performanc e To Eliminate Lymphatic Filariasis	20 19	Plos Neglecte d Tropical Diseases	Mozam bique, Democ ratic Republi c of the Congo	Cabo Delgad o, Nampu la, Niassa and Zambe zia, Kongo Central provinc e, Kuimba district, Kasai	399	whole comm unity	compl iance	longit udinal	RCS	no	no	yes	yes	no	n	У е s	no	no	2 time points	NA	NA	ALB and IVM	NA	Table 2, Table 3	repeateed c compliance	ross-sectional a	ssumed
Infectivity Of Simulium Damnosum SI And Therapeutic Coverage Of Ivermectin Distribution 10 Years Post Treatment Around Owena Dam, Ondo State, Nigeria	20 19	The Brazilian Journal Of Infectiou s Diseases : An Official Publicati on Of The Brazilian Society Of Infectiou s Diseases	Nigeria	Owena Dam, Ondo state	425	whole comm unity	compl	longit udinal	both	no	yes	no	yes	n	n o	n o	yes	no	Ever taken - in lifetime, and previous ly taken at last round	100	E	IVM	NA	Table 2, Table 3	longitudinal	compliance	
Progress Towards Lymphatic Filariasis Elimination In Ghana From 2000- 2016: Analysis Of Microfilaria Prevalence Data From 430 Communitie S	20 19	Plos Neglecte d Tropical Diseases	Ghana	nation al			undefi ned	longit udinal	RCS	yes	yes	no	yes	n o	n o	y e s	no	no	15 annual rounds of MDA	NA	NA	IVM, ALB	ivermectin (150 ?g/kg) and albendazol e (400 mg)	Figure 3			at risk population
The Division Of Labour Between Community Medicine Distributors Influences The Reach Of Mass Drug Administrati on: A Cross- Sectional Study In Rural Uganda	20 19	Plos Neglecte d Tropical Diseases	Uganda	Mayug e District	6148	whole comm unity	compl	cross- sectio nal	assum ed compl iance	no	no	no	yes	y e s	y es	y e s	no	no	N/A	NA	NA	praziquantel, ivermectin		First para in results	assumed complian ce	not given	eligible population
Using Intervention Mapping To Design And Implement Quality Improvemen t Strategies	20 19	Plos Neglecte d Tropical Diseases	Ghana	Bole	176857	whole comm unity	compl iance	longit udinal	RCS	no	yes	no	yes	n o	n o	y e s	no	no	pre and post interven tion	NA	NA	DEC, IVM, ALI	В	Table S1		eligible participa nts receiving	eligible population

Towards Elimination																											
Of Lymphatic Filariasis In Northern Ghana																											
A Rapid Appraisal Of Factors Influencing Praziquantel Treatment Compliance In Two Communitie s Endemic For Schistosomi asis In Cote D'ivoire	20 18	Tropical Medicine And Infectiou s Disease	lvory Coast	Moron ou and Bigouin	5733	SAC	undefi ned	cross- sectio nal	undefi ned	no	yes	yes	yes	n	y es	n	no	no	N/A	NA	NA	PZQ	Praziquant el tablets (Cesol* 600 mg)	Table 1	undefine d	not given	total population
An Impact Evaluation Of Two Rounds Of Mass Drug Administratii on On The Prevalence Of Active Trachoma: A Clustered Cross Sectional Survey	20 18	Plos One	Nigeria	Nasara wa State	3990	whole comm unity	undefi ned	cross- sectio nal	undefi ned	no	no	yes	yes	n o	n o	n o	no	ye s	N/A	NA	NA	Azithromy cin	NA	In text - under Fig 2	undefine d	not given	not given
Audit Of The Community- Directed Treatment With Ivermectin (Cdtl) For Onchocercia sis And Factors Associated With Adherence In Three Regions Of Cameroon	20 18	Parasites & Vectors	Camer oon	Bafia, Foumb ot- Massa ngam and Yabassi	230000	whole comm unity	compl	longit udinal	both	yes	yes	yes	yes	n	n o	n o	yes	no	Ever taken - 5 years, and taken last year		E	ivermectin	NA	programmati coverage in text, longitudinal compliance Figure 2, Figure 7, 8 and Table 1 for age/gender	longitudi nal and cross- sectional complian ce	eligible participa nts swallowi ng	eligible population
Comparison Of Mass Azithromyci n Coverage Targets Of Children In Niger: A Cluster- Randomized Trachoma Trial	20 18	The America n Journal Of Tropical Medicine And Hygiene	Niger	Matam eye District	2272	whole comm unity	undefi ned	longit udinal	RCS	no	no	no	yes	n o	n o	n o	no	ye s	7 biannual rounds over 3 years	NA	NA	Azithromy cin	NA	Table 2 (Figure 1 for denom)	undefined		
Comparison Of The Impact Of Different Mass Drug Administrati on Strategies On Infection With Schistosoma Mansoni In Mwanza Region, Tanzania-A Cluster- Randomized	20 18	The America n Journal Of Tropical Medicine And Hygiene	Tanzani a	Mwanz a	14620	other	compl	longit udinal	RCS	no	no	no	yes	n o	y es	n o	no	no	4 years, 6 interven tion arms	NA	NA	Praziquantel		Table 3	assumed co	npliance	eligible population

Controlled Trial																											
Coverage Of Azithromyci n Mass Treatment For Trachoma Elimination In Northwester n Ethiopia: A Community Based Cross- Sectional	20 18	Bmc Ophthal mology	Ethiopi a	Awi Zone	5826	whole comm unity	compl iance	longit udinal	indivi dual	yes	yes	no	yes	n o	n o	n o	no	ye s	6 rounds over 6 years - self reported complia nce at each round	6	A	Azithromy cin	NA	Figure 1	longitudi nal complian ce	eligible participa nts swallowi ng	eligible population
Study Elimination Of Onchocercia sis From Colombia: First Proof Of Concept Of Concept Of River Blindness Elimination In The World	20 18	Parasites & Vectors	Colomb ia	Naicion á	1200	whole comm unity	compl	longit udinal	RCS	no	no	no	yes	no	n	n o	yes	no	annual rounds from 1996- 2007	NA	NA	Ivermectin	na	Figure 1	assumed cor	npliance	eligible population
Evaluation Of Mass Drug Administrati on For Filariasis In Boudh District, Odisha	20 18	Journal Of Evolutio n Of Medical And Dental Sciences- Jemds	India	Boudh district, Odisha	1547	whole comm unity	compl iance	cross- sectio nal	assum ed compl iance	yes	no	yes	yes	n o	n o	y e s	no	no	N/A	NA	NA	DEC and ALB	NA	Table 3	assumed complian ce	not given	eligible population
Evaluation Of Onchocercia sis Control In The Upper Denkyira East Municipal In The Forest Area Of Ghana: Responses Of Participants And Distributors To The Cdti Programme	20 18	Acta Tropica	Ghana	Upper Denkyi ra East munici pal	692	whole comm unity	compl	longit udinal	RCS	yes	yes	yes	yes	n	n o	n o	yes	no	3 available timepoi nts	NA	NA	Ivermectin		Table 1, 2, and 4	compliance		
Programme Programme Evaluation Of Treatment Coverage And Enhanced Mass Drug Administrati on For Onchocercia sis And Lymphatic Filariasis In Five Local Government Areas Treating Twice Per Year In Edo State, Nigeria	20 18	The America n Journal Of Tropical Medicine And Hygiene	Nigeria	Edo	4942	whole comm unity	compliance	longit udinal	RCS	no	no	no	yes	n o	n o	y e s	yes	no	two rounds, 6 months apart	NA	NA	ALB, IVM	NA	Table 2, Table 3, Table 4	assumed complian ce	eligible participa nts swallowi ng	not given

Feasibility Of School- Based Health Education Intervention To Improve The Compliance To Mass Drug Administrati on For Lymphatic Filariasis In Lalitpur District, Nepal: A Mixed Methods Among Students, Teachers And Health Program	20 18	Plos One	Nepal	Lalitpu r district	572	SAC	compl	longit udinal	RCS	no	no	no	yes	n 0	no	У е s	no	no	pre and post interven tion	NA	NA	NA	NA	Table 3	assumed cor	mpliance	eligible population
Manager How Elimination Of Lymphatic Filariasis As A Public Health Problem In The Kingdom Of Cambodia Was Achieved	20 18	Infectiou s Diseases Of Poverty	Cambo dia	Rovien g, Ratana kiri, Angkor Chum, Siem Reap, Varin, Stung Treng	557859	whole comm unity	compl	longit udinal	RCS	no	no	yes	yes	no	no	y e s	no	no	5 annual rounds, reported and survey complia nce	NA	NA	DEC and ALB	NA	Table 2	complian ce	eligible participa nts swallowi ng	eligible population
Impact Of Five Annual Rounds Of Mass Drug Administrati on With Ivermectin On Onchocercia sis In Sierra Leone	20 18	Infectiou S Diseases Of Poverty	Sierra Leo	ne	2775468	whole comm unity	compl iance	longit udinal	RCS	no	no	yes	yes	n o	n o	n o	yes	no	5 annual rounds	NA	NA	IVM, ALB	NA	Table 2 - compliance for 5 years over 12 districts	assumed complian ce	eligible participa nts treated	eligible population
Impact Of Repeated Annual Community Directed Treatment With Ivermectin On Loiasis Parasitologic al Indicators In Cameroon: Implications For Onchocercia sis And Lymphatic Filariasis Elimination In Areas Co- Endemic With Loa Loa In Africa	20 18	Plos Neglecte d Tropical Diseases	Camer oon	Nation al	3684	whole comm unity	compl	longit udinal	indivi dual	yes	yes	yes	yes	n 0	no	n o	yes	no	Ever taken - self reported compila nce - 1 to 11+ rounds/ years	12		IVM	single dose	Figure 2	assumed longitudi nal complian ce	not given	eligible population
Lymphatic Filariasis Control In Tanzania: Infection, Disease	20 18	Parasites & Vectors	Tanzani a	Tanga District	737	whole comm unity	compl iance	cross- sectio nal	assum ed compl iance	no	no	no	yes	n o	n o	y e s	no	no	N/A	NA	NA	NA	NA	Table 1	assumed complian ce	participa nts swallowi ng	not given

Perceptions And Drug Uptake Patterns In An Endemic Community After Multiple Rounds Of Mass Drug Administrati on																											
Lymphatic Filariasis Transmissio n In Rufiji District, Southeaster n Tanzania: Infection Status Of The Human Population And Mosquito Vectors After Twelve Rounds Of Mass Drug Administrati on	20 18	Parasites & Vectors	Tanzani a	Rufiji District	854	whole comm unity	compl	longit udinal	both	no	no	no	yes	n o	n o	у e s	no	no	Ever taken - over past 12 years and taken last year	12	E	Ivermectin and albendazol e	ivermectin (150-200 mg/kg) and albendazol e (400 mg)	Table 1	assumed longitudi nal complian ce	eligible participa nts swallowi ng	eligible population
Mass Drug Administrati on (Mda) For Elimination Of Lymphatic Filariasis: Experiences From Nayagarh District Of Odisha, India	20 18	Indian Journal Of Commun ity Health	India	Nayaga rh District of Odisha	590	whole comm unity	compl iance	cross- sectio nal	compl iance	no	yes	yes	yes	n o	n	y e s	no	no	N/A	NA	NA	DEC and ALB	NA	Table 2 and 3	complian ce	eligible participa nts swallowi ng	eligible population
Perceived Threat And Benefit Toward Community Compliance Of Filariasis' Mass Drug Administrati on In Pekalongan District, Indonesia	20 18	Risk Manage ment And Healthca re Policy	Indone sia	Pekalo ngan district	600	adults	undefi ned	cross- sectio nal	undefi ned	no	yes	no	yes	n o	n o	У e s	no	no	N/A	NA	NA	DEC, ALB	NA	Table 3	undefine d	not given	not given
Progress On Elimination Of Lymphatic Filariasis In Sierra Leone	20 18	Parasites & Vectors	Sierra Leor	ne	4234375	whole comm unity	compl iance	longit udinal	RCS	no	no	yes	yes	n o	n o	y e s	no	no	2 annual rounds	NA	NA	lvermectin		Table 1	assumed co	npliance	eligible population
The Prevalence Of Lymphatic Filariasis Infection And Disease Following Six Rounds Of Mass Drug Administrati on In Mandalay Region, Myanmar	20 18	Plos Neglecte d Tropical Diseases	Myanm ar	Manda lay Region	1014	whole comm unity	compl iance	longit udinal	both	no	yes	yes	yes	n	n o	y e s	no	no	Ever taken - no time limit (max 6), and last round of MDA	6	E	albendazol e and diethylcar barnazine	NA	In text, fig 5, Supp Table 1	assumed lor compliance	gitudinal and cr	oss-sectional

Adherence To Ivermectin Is More Associated With Perceptions Of Community Directed Treatment With Ivermectin Organization Than With Onchozercia sis Beliefs	20 17	Plos Neglecte d Tropical Diseases	Camer oon	e Centre- West area of Camer oon	1272	adults	compl iance	longit udinal	both	no	no	yes	yes .	no	n o	n o	yes	no	Ever taken - in lifetime, and previous ly taken at last round	100	E	ivermectin	NA	Table 3	longitudinal compliance	and cross-secti	onal
Albendazole And Vermectin For The Control Of Soil- Transmitted Helminths In An Area With High Prevalence Of Strongyloide s Stercoralis And Hookworm In Northwester n Argentina: A Community- Based Pragmatic Study	20 17	Plos Neglecte d Tropical Diseases	Argenti na	Tartaga I	4891	whole comm unity	compl iance	cross- sectio nal	assum ed compi iance	no	no	γes	yes	Y e s	no	n o	no	no	N/A	NA	NA	ALB and IVM		Table 1	complian ce	eligible participa nts treated	eligible population
Assessing The Benefits Of Five Years Of Different Approaches To Treatment Of Urogenital Schistosomi asis: A Score Project in Northern Mozambiqu e	20 17	Plos Neglecte d Tropical Diseases	Mozam bique	Cabo Delgad o	81167	whole comm unity	compl iance	longit udinal	RCS	no	no	no	yes	no	У es	n o	no	no	sMDA and cMDA figures	NA	NA	Praziquant el	40mg/kg using a WHO dose pole	Table 5	complian ce	eligible participa nts swallowi ng	eligible population
e Cluster Randomized Trial Comparing School- Based Mass Drug Administrati on Areas Of Western Kenya With Moderate Initial Prevalence Of Schistosoma Mansoni Infections	20 17	Plos Neglecte d Tropical Diseases	Kenya	Nyanza Provinc e	7208	SAC	compl	longit udinal	RCS	no	no	no	yes	n o	y es	n	no	no	4 annual rounds, 3 interven tion arms	NA	NA	PZQ.	40mg/kg	Table 4			
Community- Directed Mass Drug	20 17	Social Science &	Uganda	Mayug e District	16357	whole comm unity	compl iance	cross- sectio nal	compl iance	no	no	no	yes	y e s	y es	y e s	no	no	N/A	NA	NA	praziquant el, albendazol	NA	Fig 1	complian ce	eligible participa nts	eligible population

Administrati on Is Undermined By Status Seeking In Friendship Networks And Inadequate		Medicine (1982)																				e, ivermectin				swallowi ng	
Trust In Health Advice Networks Effect Of Deworming On Indices Of Health, Cognition, And Education Among	20 17	The America n Journal Of Tropical Medicine And Hygiene	China	Qiando ngnan Prefect ure in Guizho u Provinc e	10000	SAC	compl iance	longit udinal	indivi dual	no	no	no	yes	y e s	n o	n o	no	no	2 rounds over 1 year - self reported at each time point	2	В	ALB	200 mg Albendazo Ie	Paragraqh at bottom of results	assumed longitudi nal complian ce	not given	eligible population
Schoolchildr en In Rural China: A Cluster- Randomized Controlled Trial Evaluation	20	The	Tanzani	Tukuyu	948	whole	compl	cross-	assum	no	no	no	yes	n	n	n	yes	no	N/A	NA	NA	lvermectin	NA	Table 1	assumed	not given	eligible
Of Onchocercia sis Transmissio n In Tanzania: Preliminary Rapid Field Results In The Tukuyu Focus, 2015	17	America n Journal Of Tropical Medicine And Hygiene	a	focus		comm unity	iance	sectio nal	ed compl iance		-			0	0	0	,								complian ce		population
Field-Based Evidence Of Single And Few Doses Of Annual Ivermectin Treatment Efficacy In Eliminating Skin Microfilaria Load After A Decade Of Intervention	20 17	Ethiopia n Journal Of Health Sciences	Nigeria	Kaduna State	438	adults	compl iance	longit udinal	indivi dual	no	no	yes	yes	n	n o	n o	yes	no	10 rounds over 10 years - self reported complia nce to each round	10	A	lvermectin	NA	Figure 1, Table 1	assumed longitudi nal complian ce	not given	not given
Fifteen Years Of Programme Iimplementa tion For The Elimination Of Lymphatic Filariasis In Ghana: Impact Of Mda On Immunopar asitological Indicators	20 17	Plos Neglecte d Tropical Diseases	Ghana	nation al		whole comm unity	undefi ned	longit udinal	RCS	no	no	no	yes	n o	n o	y e s	no	no	national coverag e over the past 15 years	NA	NA	ivermectin	<u>.</u>	Figure 1	assumed cov	erage	
Impact Of Mass Drug Administrati on For Elimination Of Lymphatic Filariasis In Nepal	20 17	Plos Neglecte d Tropical Diseases	Nepal	Multipl e		SAC	undefi ned	longit udinəl	RCS	no	no	yes	yes	n	n o	y e s	no	no	6 annual rounds	NA	NA	ALB and DEC		Table 1	undefined		

Important Progress Towards Elimination Of Onchocercia sis In The West Region Of	20 17	Parasites & Vectors	Camer oon	West Region	2058	whole comm unity	compl iance	longit udinal	both	yes	no	yes	yes	n o	n o	n	yes	no	Ever taken - 5 years, and taken last year	5	E	lvermectin	NA	Figure 6, Figure 7	longitudi nal complian ce	eligible participa nts swallowi ng	total population
Cameroon Lymphatic Filariasis Elimination Efforts In Rufiji, Southeaster n Tanzania: Decline In Circulating Filarial Antigen Prevalence In Young School Children Atter Twelve Rounds Of Mass Drug Administrati on And Utilization Of Long- Lasting Insecticide- Treated Nets	20 17	Internati onal Journal Of Infectiou S Diseases : Ijid : Official Publicati on Of The Internati onal Society For Infectiou S Diseases	a	Rufiji	200000	whole comm unity	compl	longit udinal	RCS	no	no	no	yes	no	no	у e s	no	no	2 time points	NA	NA	IVM, ALB	ivermectin (150-200 mg/kg) and albendazol e (400 mg)	Table 3	repeated cross- sectional complian ce	eligible participa nts swallowi ng	eligible population
Mass Drug Administrati on In Central Equatoria, South Sudan: Results And Suggestions For Future Distributions	20 17	Internati onal Health	South Sudan	Central Equato ria	196725	SAC	compl iance	longit udinal	RCS	no	no	yes	yes	y e s	y es	n o	no	no	2 biannual treatme nts in 1 year	NA	NA	ALB and PZQ	1	Table 2	compliance		
Prevalence And Risk Factors Associated With Lymphatic Filariasis In American Samoa After Mass Drug Administrati on	20 17	Tropical Medicine And Health	Americ an Samoa	nation al	1881	whole comm unity	compl iance	longit udinal	both	no	no	no	yes	n o	n	y e s	no	no	Ever taken - over 7 years, and taken at last round	7	E	albendazol e and diethylcar bamazine	NA	Table 3 and 6	assumed cro and longituc compliance		eligible population
Reaching Endpoints For Lymphatic Filariasis Elimination- Results From Mass Drug Administrati on And Nocturnal Blood Surveys, South Gujarat, India	20 17	Plos Neglecte d Tropical Diseases	India	South Guji	arat	whole comm unity	compl	longit udinal	RCS	no	no	no	yes	n	n o	y e s	no	no	6 annual rounds	NA	NA	DEC and ALB		Table 2			
The Interruption Of Onchocerca Volvulus	20 17	Plos One	Uganda			whole comm unity	compl iance	longit udinal	RCS	no	no	no	yes	n o	n o	y e s	no	no	1993- 2014	NA	NA	lvermectin ar	id ALB	Fig 2 and 3			

And Wuchereria Bancrofti Transmissio n By Integrated Chemothera py In The Obongi Focus, North Western Uganda	20	Plos	Tops	Binah	2000	whole													N/A	NA	NA	Alb, Ivm	WHO	Table 3		soticing	
Accuracy Of Coverage Survey Recall Following An Integrated Mass Drug Administrati on For Lymphatic Filariasis, Schistosomi asis, And Soli- Transmitted Helminthiasi S	20 16	Neglecte d Tropical Diseases	Togo	District	2000	comm unity	compl iance	cross- sectio nal	assum ed compl iance	yes	yes	no	yes	y e s	y es	y s	yes	no	N/A			and Pzq	guidelines		assumed complian ce	participa nts swallowi ng	not given
Controlling Neglected Tropical Diseases (Ntds) In Haiti: Implementa tion Strategies And Evidence Of Their Success	20 16	Plos Neglecte d Tropical Diseases	Haiti	Nation al			undefi ned	longit udinal	RCS	no	no	yes	yes	y e s	n o	y e s	no	no		NA	NA	400 mg of alb (ALB) and an dose of diethylcarban	age-based nazine (DEC)	Table 1	compliance		
Improving Coverage And Compliance In Mass Drug Administratii on For The Elimination Of Lf In Two 'Endgame' Districts In Indonesia Using Micronarratii ve Surveys	20 16	Plos Neglecte d Tropical Diseases	Indonesia		631	adults	compl	longit udinal	both	no	yes	yes	yes	n	n	y s	no	no	Ever taken - no limit given, and previous ly taken	100	E	NA	NA	Table 2	longitudinal compliance	and cross-secti	nal
Praziquantel Coverage In Schools And Communitie S Targeted For The Elimination Of Urogenital Schistosomi asis In Zanzibar: A Cross- Sectional Survey	20 16	Parasites & Vectors	Tanzani a	Zanzib ar	15612	whole comm unity	compl iance	cross- sectio nal	assum ed compl iance	yes	yes	yes	yes	n o	y es	n o	no	no	N/A	NA	NA	ALB,PZQ	praziquant el (40 mg/kg) for schistoso miasis and albendazol e (400 mg) for soil- transmitte d helminthia sis	Table 1	assumed complian ce	eligible participa nts swallowi ng	not given
Relationship Between Community Drug Administrati on Strategy	20 16	Plos Neglecte d Tropical Diseases	Australi a	Multiple c	ommunities	other	undefi ned	longit udinal	RCS	no	no		yes	n o	n o	n o	no	ye s		NA	NA	azithromycin		Table 3 has coverage dat	a for 0-14 years	old	

And Changes In Trachoma Prevalence, 2007 To 2013																											
Still Mesoendem ic Onchocercia sis In Two Cameroonia n Community- Directed Treatment With Ivermectin Projects Despite More Than 15 Years Of Mass Treatment	20 16	Parasites & Vectors	Camer oon	Bafia and Yabassi	756	whole comm unity	compl iance	longit udinal	both	yes	no	yes	yes	n	n	n	yes	no	Ever taken - 5 years, and taken last year	5	E	Ivm	NA	Fig 8, 9	longitudinal sectional cor		eligible population
Surveillance And Azithromyci n Treatment For Newcomers And Travelers Evaluation (Asante) Trial: Design And Baseline Characteristi Cs	20 16	Ophthal mic Epidemi ology	Tanzani a	Kongw a	NA	SAC	compl iance	cross- sectio nal	assum ed compl iance	no	no	no	yes	n o	n o	n o	no	ye s	N/A	NA	NA	Azithromy cin	single dose of 20mg/kg up to 1gm of azithromy cin, was administer ed using height- based dosing	Table 3	assumed complian ce	not given	not given
Sustaining Control Of Schistosomi asis Mansoni In Western Cote D'ivoire: Results From A Score Study, One Year After Initial Praziquantel Administrati on	20 16	Plos Neglecte d Tropical Diseases	lvory Coast	Cavally , Guemo n, Haut- Sassan dra, and Tonkpi	31832	SAC	compl iance	cross- sectio nal	compl iance	no	no	yes	yes	n o	y es	n	no	no	N/A	NA	NA	Praziquant el	praziquant el (40 mg/kg) using a dose pole	text - coverage of sbt and supplementary table 2	complian ce	eligible participa nts swallowi ng	eligible population
Mapping And Modelling The Impact Of Mass Drug Adminstrati on On Filariasis Prevalence In Myanmar	20 18	Infectiou s Diseases Of Poverty	Myanm ar	All endemi c district s	36407716	whole comm unity	undefi ned	longit udinal	RCS	no	no		yes	n o	n	y e s	no	no		NA	NA	ALB and DEC		Table 2		eligible participa nts swallowi ng	total population